"NCT00004984","Inclusion Criteria:#          -  Individuals 3-45 years old who have an immediate family member with type 1 diabetes             (such as a child, parent, or sibling)#          -  Individuals 3-20 years old who have an extended family member with type 1 diabetes             (such as a cousin, niece, nephew, aunt, uncle, grandparent, or half-sibling)#        Exclusion Criteria:#          -  To be eligible, a person must:#          -  Not have diabetes already.#          -  Have no previous history of being treated with insulin or oral diabetes medications.#          -  Have not received any prior therapy for prevention of type 1 diabetes such as             insulin, nicotinamide, or immunosuppressive drugs (i.e. have not been involved in any             previous clinical studies of these agents.)#          -  Have no known serious diseases.#          -  If you are a woman, you must not be planning to become pregnant during the course of             the study. You will not be excluded from participation, but are not encouraged to             volunteer in the first place if you plan to have a baby during the trial period).","both","3 years","45 years"
"NCT00005665","Inclusion Criteria:#          -  Newly diagnosed type 1 diabetes (within one month of diagnosis).#          -  IDDM patients: Prepubescent, adolescent, or early adult patients.#        Exclusion Criteria:#          -  Patients below the age of 3 or over 25.#          -  Patients will not be eligible if they are on immunosuppressive or immunostimulatory             medications such as azathioprine, oral nicotinamide, superoxide             dismutase-desferroxamine, vitamin E, aminoguanidine, oral insulin or other             experimental therapies at any time.#          -  Patients with a history of alcoholism, renal, cardiac, or pulmonary disease or in             whom intellectual functioning is impaired sufficiently to interfere with the             understanding of the protocol, or participation in the treatment and evaluation             program#          -  Patients who are pregnant or nursing, or those who are not willing to practice an             acceptable birth control method#          -  Patients with abnormal pre-treatment values on WBC or who are receiving potentially             hepatotoxic medications","both","3 years","25 years"
"NCT00021788","Inclusion Criteria:#          -  Candidates must be between the ages of 18 and 65#          -  Candidates must have had IDDM for at least 5 years and been under physician care for             at least 6 months prior to enrollment in trial.#          -  Eligible candidates will have poorly controlled insulin-dependent diabetes mellitus             (IDDM) and manifest signs and symptoms severe enough to be incapacitating. These             symptoms can include episodes of hypoglycemic unawareness (failure to recognize blood             glucose levels < 54 mg/dl) or episodes requiring the assistance of others.#          -  Candidates may have poor diabetes control despite intensive insulin therapy (HbA1c >             8.0%).#          -  Creatinine clearance should be > 60 ml/min)#          -  Body Mass Index should be less than 26#          -  Women of child-bearing age must have a negative pregnancy test and agree to follow             effective contraceptive measures for the duration of the trial.#        Exclusion Criteria:#          -  Previous or concurrent organ transplant#          -  Previous or concurrent malignancy#          -  Untreated proliferative diabetic retinopathy#          -  Unstable cardiovascular status, including positive stress echocardiography (if > age             35)#          -  Active infections, including x-ray evidence of pulmonary infection#          -  Peptic ulcer disease, gall stones, or portal hypertension#          -  Abnormal liver function tests#          -  Presence of panel reactive antibodies > 20%#          -  Creatinine clearance < 60 ml/min#          -  HbA1c  12%#          -  Serological evidence of HIV, HbsAg, or HCV#          -  Anemia (hemoglobin < 12.0)#          -  Any condition or circumstance, including psychogenic factors, that preclude             therapeutic compliance or otherwise make it unsafe to undergo an islet cell             transplant.#          -  PSA > 4 in males","both","18 years","65 years"
"NCT00021801","Inclusion Criteria:#          -  Candidates must be between the ages of 18 and 50.#          -  Candidates must have had insulin-dependent diabetes mellitus (IDDM) for at least 5             years and been under physician care for at least 6 months prior to enrollment in             trial.#          -  Eligible candidates will have poorly controlled IDDM and manifest signs and symptoms             severe enough to be incapacitating. These symptoms can include episodes of             hypoglycemic unawareness (failure to recognize blood glucose levels < 54 mg/dl) or             episodes requiring the assistance of others.#          -  Candidates may have poor diabetes control despite intensive insulin therapy (HbA1c >             8.0%).#          -  Creatinine clearance should be > 60 ml/min)#          -  Body Mass Index should be less than 26#          -  Women of child-bearing age must have a negative pregnancy test and agree to follow             effective contraceptive measures for the duration of the trial.#        Exclusion Criteria:#          -  Previous or concurrent organ transplant#          -  Previous or concurrent malignancy#          -  Untreated proliferative diabetic retinopathy#          -  Unstable cardiovascular status, including positive stress echocardiography (if > age             35)#          -  Active infections, including x-ray evidence of pulmonary infection#          -  Peptic ulcer disease, gall stones, or portal hypertension#          -  Abnormal liver function tests#          -  Presence of panel reactive antibodies > 20%#          -  Creatinine clearance < 60 ml/min#          -  HbA1c > 12%#          -  Serological evidence of HIV, HbsAg, or HCV#          -  Anemia (hemoglobin < 12.0)#          -  Any condition or circumstance, including psychogenic factors, that preclude             therapeutic compliance or otherwise make it unsafe to undergo an islet cell             transplant.#          -  PSA > 4 in males","both","18 years","50 years"
"NCT00034255","Inclusion Criteria:#        Patients meeting all of the following inclusion criteria at screening can be considered        for admission to the study.#        Stage 1 and Stage 2:#          1. Male and female patients with, type 1 diabetes mellitus that are 18 through 70 years             of age, or type 2 diabetes mellitus that are 30 through 70 years of age.#          2. Patients who are insulin deficient and are diagnosed with type 1 or type 2 diabetes             mellitus, and are currently well managed with insulin, with or without metformin.#          3. Patients who have been on stable doses of insulin treatment for 90 days prior to             study randomization.#        Exclusion Criteria:#        Patients meeting any of the following exclusion criteria at screening will not be enrolled        in the study:#          1. Patients with a history of any clinically significant retinopathy, symptomatic             autonomic neuropathy, unstable angina, or kidney problems.#          2. Patients with an uncontrolled or untreated significant pulmonary, neurological             condition, or cardiovascular disease, including hypertension, congestive heart             failure, angina, or peripheral vascular disease.#          3. Patients who have received any investigational product within 30 days of admission             into the study.#          4. Patients with a history or clinical evidence of multiple organ autoimmune disorders.#          5. Patients with a medical condition, serious intercurrent illness, or extenuating             circumstance that would significantly decrease study compliance, including all             prescribed follow-up.#          6. Patients who are lactating and breastfeeding.","both","18 years","70 years"
"NCT00042458","Inclusion Criteria:#          -  HbA1c value between 7.5-9%#          -  Using multiple daily insulin injections","both","18 years",""
"NCT00042471","Inclusion Criteria:#          -  HbA1c value between 6-12%#          -  BMI <= 27 kg/m2 or BMI >=30 to <= 45 kg/m2#          -  Consistent insulin regimen for 2 months prior to screening","both","18 years","70 years"
"NCT00042601","For Healthy Volunteers:#          -  BMI >=20 to <=25kg/m2 or >=30 to <=40 kg/m2#        For Subjects with Type 1 or Type 2 Diabetes:#          -  Treated with insulin for at least 6 months prior to screening#          -  HbA1c value between 6.5-10% inclusive#          -  BMI between 20-40kg/m2","male","18 years","70 years"
"NCT00046150","INCLUSION CRITERIA:#        Subjects meeting all of the following criteria will be considered for enrollment into the        study:#          -  Men and women above the age of 18.#          -  Women are either not of childbearing potential (surgically sterile, or postmenopausal             for more than 2 years) or are not pregnant and agree to use a reliable contraceptive             measure for the duration of the study.  Reliable contraceptive measures include the             follows: systemic contraceptive (oral, implant, injections), diaphragm with             intravaginal spermicide, cervical cap, intrauterine device, or condom with             spermicide.#          -  Type 1 diabetes mellitus as established in the medical history (for the purpose of             this protocol: onset of diabetes under the age of 40 and has required continuous             insulin therapy since diagnosis).#          -  At least 1 year of continuous insulin treatment with at least 6 months of continuous             subcutaneous insulin infusion treatment immediately prior to study entry.#          -  Use of the same type of external insulin pump (MiniMed programmable pump, or             Disetronic pump type H Tron Plus V 100 or D Tron) for at least 3 months prior to             study entry.#          -  HbA1c <8.5% measured at visit 1.#          -  Ability and willingness to perform blood glucose monitoring using the             sponsor-provided blood glucose meter and subject diary at home.#        Informed consent must be obtained in writing for all subjects at enrollment into the study        (see Section 12.3).#        EXCLUSION CRITERIA:#        Subjects presenting with any of the following will not be included in the study:#          -  Active proliferative diabetic retinopathy, as defined by the application of focal or             panretinal photocoagulation or vitrectomy, in the 6 months prior to visit 1, or any             other unstable (rapidly progressing) retinopathy that may require surgical treatment             (including laser photocoagulation) during the study.#          -  Diabetes other than type 1 diabetes mellitus.#          -  History of serious ketosis episode requiring hospitalization in the 3 previous             months.#          -  History of abscess at the infusion site in the previous 3 months.#          -  Pancreatectomised subjects.#          -  Subjects who have undergone pancreas and or islet cell transplants.#          -  Likelihood of requiring treatment during the study period with drugs not permitted by             the study protocol (see Section 6.2).#          -  Treatment with any investigational drug in the last month before visit 1.#          -  History of seizure disorders.#          -  History of hypersensitivity to insulin or insulin analogues or any other excipients             in the HMR1964 or insulin aspart formulation (see the Global Investigators Brochure             [7] and the insulin aspart SPC [13] for a list of excipients).#          -  Clinically relevant cardiovascular, hepatic, neurologic, endocrine, active cancer, or             other major systemic disease making implementation of the protocol or interpretation             of the study results difficult or would, in the opinion of the investigator, preclude             the safe participation of the subject in this protocol.#          -  History of drug or alcohol abuse.#          -  Impaired hepatic function, as shown by but not limited to ALT or AST greater than             twice the normal upper limit measured at visit 1.#          -  Impaired renal function, as shown by but not limited to serum creatinine >177             micromol/L (>2.0 mg/dL) measured at visit 1.#          -  Pregnancy (as determined by pregnancy blood test at visit 1) or breast-feeding.#          -  Night shift workers.#          -  Mental condition rendering the subject unable to understand the nature, scope, and             possible consequences of the study.#          -  Subject unlikely to comply with protocol, e.g. an inability and unwillingness to             participate in adequate training, an uncooperative attitude, inability to return for             follow-up visits, and unlikelihood of completing the study.#          -  Employee of the sponsor or of sponsor representatives.#          -  Subjects who have previously been treated with HMR1964.","both","18 years",""
"NCT00063128","Inclusion Criteria:#          -  You are at least 18 years old.#          -  You have had type 1 diabetes for at least 2 years.#          -  You are injecting insulin lispro (Humalog), an insulin lispro mixture (Humalog             Mixture), regular human insulin mixture (Humulin mixture) before meals using a             syringe or injection pen, not an insulin pump.#          -  If you are female and could become pregnant, you test negative for pregnancy based on             blood test at the beginning of the study, do not intend to become pregnant, and agree             to use a form of birth control approved by the investigator during the study.#          -  You have not smoked for at least 1 year, and you agree not to smoke or use smokeless             tobacco during the study.#        Exclusion Criteria:#          -  You have used an experimental drug during the last 30 days or have ever taken part in             a study of any type of inhaled insulin.#          -  You have a history of asthma or allergies.#          -  You have a chronic cough.#          -  You have had a kidney transplant, are on dialysis, or have poor kidney function.#          -  You have a history of chest pain, heart attack, or you have a heart condition that             limits your physical activity due to discomfort.","both","18 years",""
"NCT00067886","Type 1 Diabetes with or without kidney disease and past puberty.","both","14 years","40 years"
"NCT00071448","Inclusion Criteria:#          -  Pediatric patients with Type 1 diabetes for at least one year#          -  HbA1c less than 12%#          -  Willing to administer at least 3 injections per day,#          -  Willing to perform self monitored blood glucose (SMBG) at least 4 times per day,             includes subject and/or parent/guardian, as necessary","both","6 years","18 years"
"NCT00073281","-  Patients with type 1 diabetes with stable renal allografts","both","18 years","65 years"
"NCT00095082","Inclusion Criteria:#          -  Type 1 diabetes for at least 12 months#          -  Current treatment with basal-bolus insulin regimen for more than or equal to 3 months#          -  HbA1c less than or equal to 11.0%#        Exclusion Criteria:#          -  Proliferative retinopathy or maculopathy#          -  Recurrent major hypoglycaemia#          -  Impaired hepatic or renal function#          -  Cardiac problems or uncontrolled hypertension","both","18 years",""
"NCT00095446","Inclusion Criteria:#          -  People with Type I or Type II Diabetes#          -  18 Years or Older.","both","18 years",""
"NCT00097071","Inclusion Criteria:#          -  Type 1 Diabetes","both","3 years","18 years"
"NCT00097292","Inclusion Criteria:#          -  Individuals 1 to 45 years old who have an immediate family member  with type 1             diabetes (such as a child, parent, or sibling)#          -  Individuals 1-20 years old who have an extended family member with type 1 diabetes             (such as a cousin, niece, nephew, aunt, uncle, grandparent, or half-sibling)#        Exclusion Criteria:#        To be eligible a person must not:#          -  Have diabetes already#          -  Have a previous history of being treated with insulin or oral diabetes medications.#          -  Currently be using systemic immunosuppressive agents (topical and inhaled agents are             acceptable)#          -  Have any known serious diseases","both","1 year","45 years"
"NCT00100178","Inclusion Criteria:#        Potential participants must meet the following inclusion criteria:#          -  Be within 3-months of diagnosis of type 1 diabetes based on American Diabetes             Association (ADA) criteria#          -  Be between the ages of 8 and 45 years old#          -  Must have stimulated C-peptide levels > 0.2 pmol/ml (measured during an MMTT             administered no more than one month prior to the date of randomization)#          -  Must have either detectable anti-GAD, anti-ICA512/IA-2, insulin autoantibodies             (unless received insulin therapy for 7 days or more), or islet cell autoantibodies.#        [The reason for inclusion of these enrollment criteria is to avoid inclusion of patients        with ""Type 1B diabetes mellitus"", which may not involve the immunologic criteria measured        by the assays that will be utilized.]#          -  If participant has reproductive potential, he or she must be agreeable to an             effective form of birth control (unless abstinence is the chosen method).#          -  If participant is female with reproductive potential, she must be willing to undergo             pregnancy testing and to report possible or confirmed pregnancies promptly during the             course of the MMF/DZB study.#          -  Must be willing to comply with intensive diabetes management.  The goal of management             will be an HbA1c of  7.0% for all participants, regardless of age.  Participants will             be expected to take a sufficient number of daily insulin shots to meet this goal.             Alternatively, participants can use insulin pump therapy.  Participants will also be             expected to test their blood sugar at least 3-4 times per day.  There will be a             Certified Diabetes Educator working with study participants to achieve these goals.#        Exclusion Criteria:#        Potential participants must not meet any of the following exclusion criteria:#          -  Have any complicating medical issues that would interfere with blood drawing or             monitoring.#          -  Have a Body Mass Index (BMI) that is greater than the 95th percentile for age and             gender.#          -  Have serologic evidence of HIV infection.#          -  Have serologic evidence of Hepatitis B infection.#          -  Have serologic evidence of Hepatitis C infection.#          -  Have abnormal liver function tests.#          -  Have a history of leukopenia and/or neutropenia.#          -  Have a history of chronic peptic ulcer disease, erosive esophagitis, chronic             inflammatory bowel disease and/or chronic colonic disease.#          -  Have a positive PPD test result.#          -  Have had any live vaccinations in the preceding 6 weeks (e.g. MMR-second dose, live             flu vaccine, varicella vaccine, live polio vaccine, yellow fever vaccine).#          -  Resides outside reasonable geographical proximity to the clinic (i.e., residence             outside the state in which the Investigator and study reside, residence outside an             immediately neighboring state, or residence outside an area that the Investigator             considers reasonable). It is left to the Investigator's discretion to decide if a             patient's geographical residence is prohibitive to complete study participation.#          -  Require chronic use of steroids or other immunosuppressive agents for other             conditions.#          -  Be currently pregnant or 3 months postpartum.#          -  Be currently nursing or within 6 weeks of having completed nursing.#          -  Anticipate getting pregnant, or fathering a child, during the study.","both","8 years","45 years"
"NCT00105352","-  Informed consent obtained from participants (over 12 years of age) and parents (for             participants below 18 years of age).  Assent is obtained from younger children.#          -  Age 8 - 35 years at the time of inclusion#          -  Body weight > 30 kg#          -  Type 1 diabetes defined by: ADA (American Diabetes Association) criteria or judgment             of physician#          -  Duration of diabetes: 1 month to 3* years (*The TrialNet Coordinating Center will             monitor fasting C-peptide levels as they are reported to ensure that a wide range of             values is included.  This review may result in widening the duration of diabetes             window to allow for subjects with low C-peptide).#          -  Must maintain good glycemic control#          -  Be willing to travel to a TrialNet Clinical Center for a minimum of four separate             visits that are spaced 3-10 days apart, and be willing to complete the study within a             six week period.#        Exclusion Criteria:#          -  Actual treatment with drugs influencing beta cell function (e.g. oral hypoglycaemic             agents, beta-2-receptor agonists)#          -  Actual treatment with drugs influencing insulin sensitivity (e.g. steroids)#          -  Significant concomitant disease likely to interfere with glucose metabolism (e.g.             febrile illness within the prior 3 days)#          -  Expected poor compliance#          -  If a female of child-bearing age, currently pregnant or not using a form of birth             control#          -  Any other condition that by the judgement of the investigator may be potentially             harmful to the patients","both","8 years","35 years"
"NCT00107107","Inclusion Criteria:#          -  The subject has completed the full dosing period in Protocol 137-150.","both","18 years",""
"NCT00108004","Inclusion Criteria:#          -  The subject has a clinical diagnosis of type 1 diabetes mellitus requiring treatment             with insulin for a minimum of 6 months at Screening; -OR- The subject has a clinical             diagnosis of type 2 diabetes requiring treatment with insulin with or without oral             antidiabetic agents for a minimum of 6 months at Screening.#          -  The subject has a HbA1c of 7.0% to 11.0% at Screening.","both","18 years",""
"NCT00109434","Inclusion Criteria:#          -  Clinical diagnosis of type 1 diabetes for at least 18 months#          -  HbA1c <10.0% as measured by the DCA2000.#          -  Age 10.0 to <18.0 years#          -  Weight >36.0 kg#          -  BMI (body mass index) >5th and <95th percentiles for age/gender#          -  Stable insulin regimen for at least 1 month and not anticipating a change prior to             the subject's completion of the study#          -  Insulin regimen involves either use of an insulin pump or Lantus (with short-acting             insulin)#          -  NPH or Lente, if part of the insulin regimen, is given only in the morning before             breakfast#          -  Normal hematocrit (within normal limits of local laboratory)#          -  Normal thyroid function (measured within the previous year)#          -  Parent/guardian and subject understand the study protocol and agree to comply with it#          -  Informed Consent Form signed by the parent/guardian and Child Assent Form signed#        Exclusion Criteria:#          -  Insulin regimen includes Ultralente/Lente or NPH at times other than the morning             before breakfast#          -  A recent injury to body or limb, Addison's disease, muscular disorder, use of any             medication or other significant medical disorder if that injury, medication or             disease in the judgment of the investigator will affect the completion of the             exercise protocol#          -  Asthma which has been medically treated within the last year#          -  Current use of glucocorticoid medication (by any route of administration)#          -  Current use of a beta blocker medication#          -  Use of pseudoephedrine 48 hours prior to CRC admission (if used in the 48 hours prior             to the scheduled second admission, the admission will be deferred)#          -  Severe hypoglycemia resulting in seizure or loss of consciousness in the 2 weeks             prior to CRC admission (if a severe episode occurs within 2 weeks prior to the             scheduled second admission, the admission will be deferred)#          -  Active infection (if at the time of the planned second admission an infection is             present, the admission will be deferred)#          -  Anticipating a significant change in exercise regimen between admissions (i.e.             starting or stopping an organized sport)","both","10 years","17 years"
"NCT00117026","Inclusion Criteria:#          -  Type 1 diabetes (of at least 15 years duration) as assessed by medical history.#        Exclusion Criteria:#          -  Macroalbuminuria#          -  Symptomatic gastroparesis. Diabetic nephropathy with a creatinine clearance less than             60 cc/min.#          -  Evidence of chronic infection.#          -  History of any malignancy.#          -  Any chronic medical condition that unduly increases the risk for the potential             enrollee as judged by study investigators.#          -  Pregnancy, breastfeeding or planned pregnancy within two years.#          -  Supplementation with thiamine > 2mg per day and/or alpha-lipoic acid#          -  Chronic alcoholism/alcohol abuse.","both","18 years","60 years"
"NCT00117780","Inclusion Criteria:#          -  Type 1 diabetes for more than 1 year#          -  Subject treated by any kind of insulin regimen and whatever the number of injections#          -  HbA1c = 7.5% and = 10%#        Exclusion Criteria:#          -  Type 2 diabetes#          -  Treatment by oral anti-diabetic drugs#          -  Severe medical conditions","both","18 years","70 years"
"NCT00118937","Inclusion Criteria:#          -  HbA1c > 8.5% for more than one year prior to enrolment.#          -  Diabetes-duration > 5 years.#          -  Age at onset of diabetes < 35 years#          -  Fasting C-peptide < 300 pmol/l#          -  Age > 18 years at enrolment.#        Exclusion Criteria:#          -  Clinical or biochemical signs of kidney-, liver- or heart-failure.#          -  Other coexisting serious morbidity, which will affect the study-participation or             outcome of the study i.e. cancer.#          -  Known abuse of any medication or alcohol#          -  Hypoglycaemia unawareness.#          -  Pregnancy or planned pregnancy in the study-period.","both","18 years",""
"NCT00118976","Inclusion Criteria:#          -  Type 1 diabetes (WHO criteria)#          -  Diabetic nephropathy (2 out of 3 consecutive 24 hour urinary samples with albumin             excretion > 300 mg/24hour and diabetic retinopathy in the absence of signs of other             kidney or urinary tract disease) 27 or diabetic glomerulosclerosis verified by             biopsy.#          -  Hypertension: Blood pressure > 135 mmHg systolic and/or 85 mm Hg diastolic             repeatedly.#          -  Age from 18 to 70 years.#        Exclusion Criteria:#          -  Age < 18 years or > 70 years.#          -  Pregnancy or fertile women not using adequate anticonceptive (intrauterine device,             sterilization, or oral anticonceptive)#          -  Malignant hypertension.#          -  Blood pressure > 180/105 mm Hg#          -  Known renal artery stenosis#          -  GFR < 30 ml/min/1.73 m²#          -  Serum potassium > 4.8 mmol/ l#          -  Heart failure, myocardial infarction, unstable angina or coronary bypass operation             within the previous three months.#          -  Abuse of drugs or alcohol.#          -  Not able to understand the written information.#          -  Known intolerance to ACE inhibitors.#          -  Chronic use of  non steroid inflammatory drugs or aspirin (above 1 g/day)","both","18 years","70 years"
"NCT00119041","Inclusion Criteria:#        1) Current prescription of insulin or an oral hypoglycemic agent;  2) A1c > 7.0%; or 3)        fasting glucose levels > 130 mg/dl; and 4) referred to see a consultant and are seen        during the active intervention phase. Patients with either Type I or Type II DM will be        included.#        Exclusion Criteria:#        1) primary care obtained at more than one site (based on stop codes with evidence of more        than 1 CBOC involved in care during the last 6 months), and 2) documented dementia,        aphasia, and psychosis.","both","18 years",""
"NCT00127634","Inclusion Criteria:#          -  Type 1 diabetes#          -  Non smoker#          -  Normal lung function#        Exclusion Criteria:#          -  Significant pulmonary, hepatic, or renal disease#          -  Severe congestive heart failure#          -  Active malignancy#          -  Systemic glucocorticoid therapy","both","18 years",""
"NCT00129259","Inclusion Criteria:#          -  Diagnosis of type 1 diabetes (according to American Diabetes Association [ADA]             criteria) within the 8 weeks prior to study entry#          -  Weigh at least 25 kg (55 lbs)#          -  Insulin autoantibodies assessed within 10 days of any insulin use OR anti-glutamic             acid decarboxylase (GAD) autoantibodies OR anti-ICA512/IA-2 autoantibodies#          -  Parent or guardian willing to provide informed consent, if applicable#        Exclusion Criteria:#          -  Prior participation in a clinical trial that could potentially affect diabetes             condition or immunologic status#          -  Participation in another investigational clinical trial within the 6 weeks prior to             study entry#          -  Pregnancy or breastfeeding","both","8 years","30 years"
"NCT00130481","Inclusion Criteria:#          -  Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM) for more than 1             year#          -  Age 10-18 years.#        Exclusion Criteria:#          -  Cardiovascular disease (CVD)#          -  Liver disease#          -  Pregnancy#          -  Use of cholesterol or triglyceride lowering drugs#          -  Perceived inability to comply with the study protocol#          -  Endocrinopathy other than diabetes","both","10 years","18 years"
"NCT00131755","Inclusion Criteria:#          -  Type 1 diabetes no longer than three months#          -  Positive antibodies against GAD or IA2#          -  Age between 18-40 years#          -  C-peptide >0.2 nmol/l#        Exclusion Criteria:#          -  Drug or alcohol abuse#          -  Severe concomitant disease#          -  Pregnancy","both","18 years","40 years"
"NCT00133809","Inclusion Criteria:#          -  Type 1 diabetes mellitus diagnosed > 5 years previously#          -  Body mass index less than or equal to 26#          -  18 to 65 years of age#          -  Compliance with an optimized diabetic management plan as assessed by an Emory             University endocrinologist#          -  Checking and recording blood sugars at least 3 times per day#          -  Intensive insulin therapy (injecting insulin at least 3 times a day or using an             insulin pump)#          -  Severe hypoglycemia and/or hyperglycemia. Severe hypoglycemia is defined by: episodes             requiring assistance by others and/or hypoglycemic unawareness (the inability to             recognize blood glucose < 54 mg/dL). Severe hyperglycemia is defined by: two episodes             of ketoacidosis requiring hospitalization within the past year.#        Exclusion Criteria:#          -  Renal dysfunction#          -  Severe co-existing cardiac disease, characterized by any one of these conditions:             recent myocardial infarction (within past six months); angiographic evidence of             non-correctable coronary artery disease; or evidence of ischemia on a dobutamine             stress echocardiogram.#          -  Current bacterial or fungal infection#          -  Macroproteinuria#          -  Baseline hemoglobin < 11.4 gm/dL in women; < 12.9 gm/dL in men.#          -  Hyperlipidemia#          -  Positive tests for human immunodeficiency virus (HIV), or hepatitis B or C#          -  Negative antibody test for varicella zoster virus (subjects may be reconsidered if             they receive the vaccination and convert to a positive antibody)#          -  History of malignancy (except squamous or basal cell skin carcinoma)#          -  Previous/concurrent organ transplantation#          -  Presence of HLA panel reactive antibodies > 20%#          -  Active peptic ulcer disease#          -  Evidence of gallbladder disease including cholecystitis and cholelithiasis#          -  Evidence of liver disease including hepatic neoplasm, portal hypertension, or             persistently abnormal liver function tests.#          -  Persistent coagulopathy or current use of anticoagulants (not including aspirin)#          -  Sickle cell anemia#          -  Positive pregnancy test, intent for future pregnancy, failure to follow effective             contraceptive measures, or presently breastfeeding#          -  Active alcohol or substance abuse.  This includes smoking (must be abstinent for six             months).  Active alcohol abuse should be considered using the current National             Institute on Alcohol Abuse and Alcoholism (NIAAA) definitions.#          -  Psychiatric disorder making the subject not a suitable candidate for transplantation#          -  Current use of systemic steroid medications#          -  Evidence of insulin resistance (insulin requirement > 1.2 units/kg/day)#          -  Inability to provide informed consent#          -  Any condition or any circumstance that makes it unsafe to undergo an islet transplant","both","18 years","65 years"
"NCT00135915","Inclusion Criteria:#          -  Type 1 diabetes for > 5 years#          -  Use of multiple daily injections of a basal insulin and a rapid acting component#          -  Regular consumption of modest amounts of alcohol#        Exclusion Criteria:#          -  Type 2 diabetes#          -  Type I diabetes < 5 years#          -  Excessive alcohol consumption#          -  Unstable diabetes","both","18 years",""
"NCT00137046","Inclusion Criteria:#          -  Type 1 diabetes mellitus#        Exclusion Criteria:#          -  severe asthma or COPD#          -  smoking#          -  brittle diabetes","both","18 years","65 years"
"NCT00140543","Inclusion Criteria:#          1. Male or female patients, of 18 to 55 years of age, with end-stage,             C-peptide-negative,  Type 1-diabetic nephropathy.#          2. Female patients of childbearing age must have a negative pregnancy test and must             agree  to maintain effective birth control practice throughout the study period (3             years).#          3. Patient must have signed the Patient Informed Consent Form.#          4. Patient must receive a primary simultaneous pancreas/kidney (SPK) cadaveric             transplant, with either intestinal or bladder and either portal or systemic venous             drainages.#        Exclusion Criteria:#          1. Patient is pregnant or breastfeeding.#          2. Patient is allergic or intolerant to Mycophenolate Mofetil, Sirolimus, Tacrolimus or             other macrolides, or any compounds structurally related to these compounds.#          3. Patient has a positive T-cell crossmatch on the most recent serum specimen.#          4. Patient is known for active liver disease or has significant liver disease, defined             by  ASAT and ALAT serum levels greater than 3 times the upper limit of normal.#          5. Patient has malignancy or history of malignancy, with the exception of adequately             treated localised squamous cell or basal cell carcinoma, without recurrence.#          6. Patient has been included in another clinical trial protocol for any investigational             drug  within 4 weeks prior to randomisation.#          7. Patient has any form of substance abuse, psychiatric disorder or condition, which, in             the  opinion of the investigator, may invalidate communication.#          8. Patient receives a SPK transplant from a living donor, or receives segmental             pancreatic  transplant, or a previous kidney transplant alone.#          9. Pancreatic duct occlusion technique .#         10. Donor is older than 55 years of age.#             -","both","18 years","55 years"
"NCT00141986","Inclusion Criteria:#          -  HLA genotypes that increase risk of type 1 diabetes:  heterozygous for DRB1*03,             DQA1*0501, DQB1*0201 / DRB1*04, DQA1*03011, DQB1*0302 (DRB1*04 ≠ *0403 or related             alleles), or  homozygous for DRB1*03, DQA1*0501, DQB1*0201, or homozygous for             DRB1*04, DQA1*03011, DQB1*0302 (DRB1*04 ≠ *0403 or related alleles).#        Exclusion Criteria:#          -  Premature, low birthweight, or major congenital malformations or serious chronic             disease","both","","4 weeks"
"NCT00142922","Inclusion Criteria:#        For Patients With Type 1 Diabetes#          -  Aged 18-65#          -  Presence of type 1 diabetes mellitus.#          -  2-25 year duration.#        For Patients With Type 2 Diabetes#          -  Aged 25-65 years#          -  presence of type 2 diabetes mellitus.#          -  2 years since initial diagnosis.#        Exclusion Criteria:#          -  Renal disease, microalbumin >300 ug/mg)#          -  Severe peripheral diabetic neuropathy and/or severe peripheral vascular disease#          -  Symptomatic severe autonomic neuropathy who may be at risk when increasing activity             levels.#          -  Women who are currently pregnant#          -  proliferative diabetic retinopathy based on dilated eye examination within one year             of study entry.  Patients whose eye disease is successfully treated will be included.#          -  HbA1c  levels less than 7.0% (normal range 4.0 - 6.0%).#          -  HbA1c  levels greater than 14.0%#          -  patients who underwent intensive insulin treatment within one year#          -  a history of severe, unstable myocardial infarction, congestive heart failure or             other severe cardiac disease, severe hypertension (systolic more than 160 mmHg or             diastolic 90 mmHg) who may be at risk when mildly increasing physical activity#          -  a DSMIV diagnosis of eating disorders including anorexia nervosa, bulimia, and severe             weight-related insulin omission.#          -  Patients with recent diagnosis (past 6 months) of bipolar disorder, schizophrenia,             mental retardation, organic mental disorder, and alcohol or drug abuse#          -  Patients whose diabetes diagnosed cannot be clearly classified as type 1 or type 2.","both","18 years","75 years"
"NCT00143104","Inclusion Criteria:#          -  Type 1 Diabetes Mellitus#          -  Normal lung function#        Exclusion Criteria:#          -  Smokers","both","18 years","55 years"
"NCT00143949","Inclusion Criteria:#          -  type 1 diabetic (DM) for 2-20 yrs#          -  type 1 DM onset prior to 45; if onset was between ages 31-41, BMI <26; onset 41-45,             positive GAD or ICA required#          -  normal or increased GFR#          -  normal BP#          -  normoalbuminuric (<20 ug/min on 2 of 3 time overnight urine collections)#        Exclusion Criteria:#          -  type 1 DM duration longer than 20 yrs#          -  hypertension (>85/135 mmHg)#          -  reduced GFR (<90 ml/min/1.73m2)#          -  microalbuminuria#          -  solitary kidney or evidence of unilateral renal disease#          -  evidence of other important kidney disease by history, ultrasound or biopsy#          -  other chronic diseases or conditions such as cystic fibrosis, serious mental illness,             severe mental retardation, etc.#          -  pregnancy or females planning pregnancy within 2 years were excluded due to the drugs             being used#          -  compliance (pt not taking at least 85% of two week placebo were excluded)","both","16 years","61 years"
"NCT00145353","Inclusion Criteria:#          -  Type 1 diabetes mellitus treated with insulin four times daily (basal bolus             treatment) at least three months before screening.#          -  AGe: 18-60 years#          -  BMI: 18-27.5#          -  No nefro- or neuropathy; i.e. S-creatinin below 120  μmol/l and normal monofilament             examination#          -  Written informed consent#        Exclusion Criteria:#          -  Pregnant women or patients planning to become pregnant during the investigation             period#          -  Reduced eyesight; i.e. visus > 0.3 evaluated at the latest eye exam.#          -  Patient lacking the ability to sens insulin sensitivity#          -  Serious rival disease, i.e. heart disease, severe liver or lung impairment, severe             psychiatric disease.#          -  Suspicion of abuse or non-compliance#          -  Participation in another clinical trial","both","18 years","60 years"
"NCT00145379","Inclusion Criteria:#          -  Patients with type 1 diabetes mellitus treated with insulin 4 times daily.#          -  Age: 18-60 years#          -  Fertile women use adequate contraception, e.g. contraceptive pills#          -  C-peptide <300 pmol/L#          -  BMI >/= 25#          -  HbA1c >/=8%#        Exclusion Criteria:#          -  Pregnant and patients planning to become pregnant during the investigation period#          -  Reduced eyesight#          -  Known kidney disease, s-creatinin >100#          -  Liver disease, Alat > 50#          -  Neuropathic patients diagnosed by clinical examination","both","18 years","60 years"
"NCT00146484","Inclusion Criteria:#          -  New onset type 1 diabetes#          -  Less than 48 hours since first insulin injection#          -  Child and/or parent able to read and write English#          -  Family intends to continue treatment at our institution for the next two years#          -  Informed consent from adolescents greater than 16 years of age, or if less than 16             years, informed consent from the parent/guardian with assent from the child.#        Exclusion Criteria:#          -  Chronic medical conditions other than treated hypothyroidism or mild asthma#          -  Concerns of the diabetes team regarding future treatment adherence making twice daily             insulin preferable to the split evening injection regimen (e.g., cognitive             impairment, severe family dysfunction).","both","","17 years"
"NCT00147342","Inclusion Criteria:#          -  Clinical diagnosis of type 1 diabetes for at least 18 months (The diagnosis of type 1             diabetes is based on the investigator's judgment; C peptide level and antibody             determinations are not needed.)#          -  HbA1c <10.0% (The DCA2000 will be used to assess eligibility.)#          -  Age 8.0 to <18.0 years#          -  Weight >39.5 kg at reinfusion centers and >46.0 kg at discard centers#          -  BMI >5th and <95th percentiles for age and gender#          -  Stable insulin regimen for at least 1 month and not anticipating a change prior to             the subject's completion of the study (Stable is defined as no change in the overall             insulin program, i.e., no change from SC injections to pump.)#          -  Insulin regimen involves use of an insulin pump#          -  Normal thyroid function (measured within the previous year)#        Exclusion Criteria:#          -  A recent injury to body or limb, Addison's disease, muscular disorder, use of any             medication or other significant medical disorder if that injury, medication or             disease in the judgment of the investigator will affect the completion of the             exercise protocol#          -  Asthma which has been medically treated within the last year#          -  Current use of glucocorticoid medication (by any route of administration)#          -  Current use of a beta blocker medication#          -  Use of pseudoephedrine 48 hours prior to visit (if used in the 48 hours prior to the             scheduled visit, the visit will be deferred)#          -  Severe hypoglycemia resulting in seizure or loss of consciousness in the 2 weeks             prior to a visit (if a severe episode occurs within 2 weeks prior to the scheduled             visit, the visit will be deferred)#          -  Active infection (if at the time of the scheduled visit an infection is present, the             visit will be deferred)#          -  Anticipating a significant change in exercise regimen between visits (i.e. starting             or stopping an organized sport)","both","8 years","17 years"
"NCT00148538","Inclusion Criteria:#          -  Type 1 diabetes mellitus as defined by the 2003 CDA guidelines (16) requiring insulin             therapy starting within one year of diagnosis and continuously thereafter#          -  Male or female, age 16-45 years, A1c 0.066-0.090#          -  Physically inactive (see exclusion criteria below)#          -  Willingness and ability to work closely with the study physicians, nurse and             dietitian and follow intensive diabetes therapy including carbohydrate counting,             glucose monitoring >= 4 times per day, and intensive insulin therapy--either by             multiple daily injections (MDI--insulin aspart or lispro before meals and NPH or             insulin glargine 1-2X/day) or continuous subcutaneous insulin infusion (CSII) by pump             therapy using insulin aspart or lispro for the duration of involvement in the study.             CSII will only be an option for those already on CSII prior to entry in the study.#        Exclusion Criteria:#          -  Participation during the previous 4 months in a regular program of exercise or             aerobic sports greater than 2 times per week for at least 20 minutes per session, or             in any resistance training.#          -  Hypoglycemia unawareness, or severe hypoglycemia requiring assistance from another             person within the previous 3 months.#          -  ""Brittle"" diabetes, characterized by frequent and unpredictable hypoglycemia (even if             not requiring assistance from others) and hyperglycemia.#          -  Restrictions in physical activity due to disease: intermittent claudication, severe             peripheral neuropathy or active proliferative retinopathy, unstable cardiac or             pulmonary disease, disabling stroke, severe arthritis.#          -  Known or suspected clinically significant gastroparesis.#          -  Body mass index less than or equal to 32 kg/m2.#          -  Fasting serum c-peptide less than 0.2 nmol/l.#          -  Recent significant weight change (increase or decrease of 5% of body weight during             the two months before enrollment).#          -  An expected requirement within the subsequent 6 months for medications (other than             insulin) that will affect glucose metabolism (e.g. corticosteroids).#          -  If age < 18 yr, linear growth of 1cm during the previous year.#          -  Significant renal disease: serum creatinine greater than 200 mEq/l. or proteinuria >             1 g/24 hours.#          -  Uncontrolled hypertension: BP > 150 mm Hg systolic or > 95 mm Hg diastolic in a             sitting position.#          -  Other illness, judged by the patient or investigators to make participation in this             study inadvisable.#          -  Cognitive deficit resulting in inability to understand or comply with instructions.#          -  Pregnancy at the start of the study, or intention to become pregnant in the next             year.#          -  Inability to communicate in English or French.#          -  Unwillingness to sign informed consent.","both","16 years",""
"NCT00160732","Inclusion Criteria:#          -  Patients must have type I diabetes mellitus, documented by undetectable C-peptide.             Patients must have been diabetic for at least five years, and be aged 18 - 58 years.#          -  Patients must be on an intensive regimen of glucose monitoring and exogenous insulin             injection (defined as greater than or equal to three checks and injections per day).             This regimen must be prescribed and supervised by the patient's diabetologist.#          -  Despite intensive therapy, patients must have at least one of the following:#               -  Brittle diabetes (metabolic instability), as defined by elevated mean amplitude                  of glycemic excursion;#               -  Hypoglycemic unawareness, with at least one episode in the past two years in                  which hypoglycemia required the assistance of another person (e.g., family                  member, emergency medical technician [EMT], etc.), and was associated with a                  fingerstick blood glucose (FSBG) of < 50 mg/dl and prompt recovery after                  administration of oral glucose, intravenous glucose, or glucagon;#               -  Progressive complications of diabetes (nephropathy manifested by proteinuria,                  retinopathy documented by an ophthalmologist after dilated eye exam, or                  neuropathy as determined by a neurologist).#          -  Patients must be able to give informed consent.#        Exclusion Criteria:#          -  Failure to meet inclusion criteria#          -  Panel of Reactive Antibody (PRA) > 10%#          -  Creatinine clearance < 80 mL/min#          -  Prior organ transplant#          -  Portal hypertension: this refers to portal hypertension diagnosed previously by any             means, or, by the investigators' evaluation, symptoms and/or signs of liver             dysfunction with or without portal hypertension including, but not limited to,             jaundice, ascites, encephalopathy, spider angiomata, coagulopathy, or peri-umbilical             venous engorgement.  Elevated portal pressures, as measured during intended islet             infusion, may also result in discontinuation of infusion.#          -  Abnormal liver function tests (> 2 times the upper limit of normal as defined by the             University of Chicago Clinical Laboratory)#          -  History of malignancy.   Any history of malignancy in a patient who has had an             ""adequate"" period of no evidence of neoplastic disease should not rule out             individuals from enrolling in this study.  Rather, pre-enrollment screening for             malignancy will follow current established guidelines as for solid-organ transplant.             These current guidelines appear in Kasiske, B.L., et al. ""The Evaluation of Renal             Transplant Candidates: Clinical Practice Guidelines,"" American Journal of             Transplantation 1 (Supplement 2): 12-22, 2001.#          -  Active peptic ulcer disease#          -  Pregnancy, or inability to comply with contraceptive regimen#          -  Severe unremitting gastroparesis or diarrhea#          -  Active infection#          -  Serologic positivity for HIV and/or hepatitis#          -  Chest radiographic abnormality consistent with neoplastic or infectious disease#          -  Major ongoing psychiatric illness and/or substance abuse#          -  Noncompliance with current medical regimen#          -  Obesity (body mass index [BMI] > 28)#          -  Any other medical condition precluding safe transplantation and immunosuppression#          -  Ejection fraction < 30%#          -  Myocardial infarction (MI) within the past 6 months#          -  Known allergies or hypersensitivity to immunosuppressive agents used in this protocol#          -  Inability to provide written informed consent.","both","18 years","58 years"
"NCT00173628","Inclusion Criteria:#          -  pediatric patients with type 1 diabetes","both","","20 years"
"NCT00173641","Inclusion Criteria:#          -  pediatric type 1 DM#        Exclusion Criteria:#        -","both","1 month","20 years"
"NCT00175253","Inclusion Criteria:#          -  open to Canadians only#          -  participant must have had Type 1 diabetes mellitus for more than 5 years#          -  diabetes must be complicated by at least 1 of the following situations that persist             despite intensive insulin management efforts: (1) Reduced awareness of hypoglycemia,             as defined by the absence of adequate autonomic symptoms at plasma glucose levels <             3.0 mmol/L, indicated by, 2 or more episodes of severe hypoglycemia requiring third             party assistance within 12 months; or (2) Metabolic instability, characterized by             erratic blood glucose levels that interfere with daily activities and or 2 or more             hospital visits for diabetic ketoacidosis over the last 12 months.#          -  Participants must be capable of understanding the purpose and risks of the study and             must sign a statement of informed consent.#        Exclusion Criteria:#          -  Severe co-existing cardiac disease#          -  Active alcohol or substance abuse, to include cigarette smoking#          -  Psychiatric disorder making the subject not a suitable candidate for transplantation#          -  History of non-adherence to prescribed regimens#          -  Active infection including Hepatitis C, Hepatitis B, HIV, TB#          -  Any history of or current malignancies except squamous or basal skin cancer#          -  BMI > 28 kg/m2 at screening visit#          -  Creatinine clearance < 65 mL/min/1.73 m2#          -  Blood creatinine > 150 µmol/L (1.7 mg/dL)#          -  Macroalbuminuria (urinary albumin excretion rate > 300 mg/24h)#          -  Baseline Hb < 105g/L (<10.5 g/dL) in women, or < 130 g/L (<13 g/dL) in men#          -  Baseline screening liver function tests outside of normal range#          -  Untreated proliferative retinopathy#          -  Positive pregnancy test, intent for future pregnancy or male subjects' intent to             procreate, failure to follow effective contraceptive measures, or presently breast             feeding#          -  Previous transplant, or evidence of significant sensitization on PRA#          -  Insulin requirement  >1.0 U/kg/day#          -  HbA1C >12%#          -  Uncontrolled hyperlipidemia#          -  Under treatment for a medical condition requiring chronic use of steroids#          -  Use of coumadin or other anticoagulant therapy (except aspirin) or subject with PT             INR > 1.5#          -  Untreated Celiac disease#          -  Patients with Graves disease will be excluded unless previously adequately treated             with radioiodine ablative therapy","both","18 years","65 years"
"NCT00175266","Inclusion Criteria:#          -  must have Type 1 diabetes mellitus for more than 5 years#          -  diabetes must be complicated by at least one of the following situations that persist             despite intensive insulin management efforts.  The complicating situations are (1)             Reduced awareness of hypoglycemia, as defined by the absence of adequate autonomic             symptoms at plasma glucose levels of < 3.0 mmol/L; (2) Metabolic             lability/instability, characterized by MAGE >= 11.0 mmol/L and wide swings in blood             glucose despite optimal diabetes therapy; and (3) Despite efforts at optimal glucose             control, progressive secondary complications of diabetes, including retinopathy,             neuropathy, or nephropathy#        Exclusion Criteria:#          -  Severe co-existing cardiac disease#          -  Active alcohol or substance abuse#          -  Psychiatric disorder making the subject not a suitable candidate for transplantation#          -  Active infection including hepatitis C, hepatitis B, HIV, or TB#          -  Any history of or current malignancies except squamous or basal skin cancer#          -  BMI > 28 kg/m2 or body weight > 85 kg at screening visit#          -  Positive fasting C-peptide response on assessment (2 positive results)#          -  Creatinine clearance < 80 mL/min/1.73 m2#          -  Serum creatinine > 150 µmol/L#          -  Macroalbuminuria (urinary albumin excretion rate > 300 mg/24h)#          -  Baseline Hb < 105g/L in women, or < 130 g/L in men#          -  Baseline LFT's outside of normal range#          -  Untreated proliferative retinopathy#          -  Positive pregnancy test, intent for future pregnancy or male subjects' intent to             procreate, failure to follow effective contraceptive measures, or presently breast             feeding#          -  Previous transplant, or evidence of sensitization on PRA#          -  Insulin requirement > 1.0 IU/kg/day#          -  HbA1C > 0.12#          -  Hyperlipidemia (fasting LDL cholesterol > 3.4 mmol/L, treated or untreated; and/or             fasting triglycerides > 2.3 mmol/L)#          -  Under treatment for a medical condition requiring chronic use of steroids#          -  Use of coumadin or other anticoagulant therapy (except aspirin) or subject with PT             INR > 1.5#          -  Untreated Addison's disease#          -  Untreated Celiac disease#          -  Untreated thyroid disease","both","18 years","65 years"
"NCT00179777","Inclusion Criteria:#          -  Biological parent and/or full (not half) sibling of the newborn infant has type 1             diabetes as defined by the World Health Organization#          -  The infant's parent or legal guardians give signed consent to participate#        Exclusion Criteria:#          -  An older sibling of the newborn infant has been included in the TRIGR intervention#          -  Multiple gestation#          -  The parents are unwilling or unable to feed the infant cow's milk based products for             any reason (e.g., religious, cultural).#          -  The newborn infant has a recognizable severe illness such as those due to chromosomal             abnormality, congenital malformation, respiratory failure needing assisted             ventilation, enzyme deficiencies, etc.#          -  The gestational age of the newborn infant is less than 35 weeks.#          -  The infant is older than 7 days at randomization.#          -  Inability of the family to take part in the study (e.g. the family has no access to             any of the Study Centers, the family has no telephone).#          -  The infant has received any infant formula other than Nutramigen prior to             randomization.#          -  No HLA sample drawn before the age of 8 days.","both","","7 days"
"NCT00184639","Inclusion Criteria:#          -  Type 1 diabetes#          -  Current intensified insulin treatment#          -  Injection of insulin Semilente®MC at bedtime for at least 6 weeks#          -  BMI maximum 32 kg/m^2#          -  HbA1c > 5.5 % and < 12.0 %#        Exclusion Criteria:#          -  Current treatment with premixed insulin(s)#          -  Impaired hepatic or renal function#          -  Recurrent major hypoglycaemia","both","6 years","21 years"
"NCT00184665","Inclusion Criteria:#          -  Type 1 diabetes#          -  Currently on basal-bolus regimen#          -  BMI = 35.0 kg/m2#          -  HbA1c =11.0%#        Exclusion Criteria:#          -  Proliferative retinopathy or maculopathy#          -  Recurrent major hypoglycaemia#          -  Cardial problems#          -  Uncontrolled hypertension#          -  Impaired hepatic or renal function","both","18 years",""
"NCT00187564","Inclusion Criteria:#          1. Subjects must be pubertal (defined as Tanner stage II or greater), or post-pubertal,             with an upper age limit of 21 years.#          2. Subjects must have diabetes by 1997 ADA criteria:#               1. fasting plasma glucose >= 126 mg/dL, or#               2. 2 hour postprandial glucose >= 200 mg/dL#          3. Subjects must have history of least one auto-antibody associated with T1D, either             glutamic acid decarboxylase (GADA) or islet cell autoantigen 512 (ICA512), or history             of diabetic ketoacidosis.#        Exclusion Criteria:#        1. Subjects must not have history of eye, kidney or nerve damage 2. Subjects must not be        deemed unable or unlikely to comply with the protocol. Children who are unable to swallow        pills, or are unwilling to take pills twice daily will be excluded from the study.#        -","both","8 years","21 years"
"NCT00190502","Inclusion Criteria:#          -  Type 1 diabetes#          -  Body mass index up to 32 kg/m2#          -  Exclusion of gravidity in women#          -  Known diagnosis of diabetes of less than 6 weeks#          -  Insulin dose of up to 40 IU per day for no longer than 1 month#          -  Positive for at least one autoantibody (GAD, IA2, ICA)#          -  C-peptide level >= 0.3 pmol/ml 4 min. following intravenous (IV) administration of 1             ml glucagon#          -  No concurrent severe infection#          -  Granulocyte count >= 2 x 10^9/l#          -  Platelet count >= 120 x 10^9/l#        Exclusion Criteria:#          -  Other non-diabetes related autoimmune disease#          -  Previous immunosuppressive therapy#          -  Any clinical impairment precluding immunosuppressive therapy#          -  Leucopenia or thrombocytopenia","both","15 years","35 years"
"NCT00191581","Inclusion Criteria:#          1. Men and women who have had either type 1 or type 2 diabetes (World Health             Organization[WHO]classification)for at least 2 months and are between the ages of 18             and 70 (inclusive) at the signing of the informed consent.#          2. Have been treated with commercially available human insulin mix 50/50 or human             insulin mix 30/70 twice daily as the only pharmacological treatment for their             diabetes for at least 2 months prior to entering the study.#          3. Have an HbA1c between 1.1 and 1.7 times the upper limit of the normal reference             rang(inclusive) as determined by a local laboratory within 2 weeks prior to or at             Visit 1.#          4. Have achieved compliance with their diets and insulin therapies as determined by the             investigators and perform regular blood glucose monitoring.#          5. Have given informed consent to participate in this study in accordance with local             regulations.#        Exclusion Criteria:#        {1] Have used oral antidiabetic agents, including biguanides, sulfonylureas, glucosidase        inhibitors, and insulin-sensitivity enhancers within 30 days prior to entry into the        study.#        [2] Receive a total daily dose of insulin >2 units/kg.#        [3] Have had more than two episodes of severe hypoglycemia (defined as requiring        assistance of another person due to disabling hypoglycemia) within 6 months prior to entry        into the study.#        [4] Have a body mass index >35 kg/m2.#        [5] Have serum creatinine > the upper limit of normal (ULN), as determined by a local        laboratory.","both","18 years","70 years"
"NCT00194558","Inclusion Criteria:#          -  Computer and Internet access at home#          -  Receiving care at the University of Washington Diabetes Care Center#        Exclusion Criteria:#          -  Non-English speaking","both","18 years","39 years"
"NCT00198146","Inclusion Criteria:#          -  Newly diagnosed type 1 diabetes without previous insulin or oral hypoglycemic             therapy.#          -  ages 2 to 40 years at diagnosis#          -  enroll within 3 months of diagnosis#          -  test positive for at least one of the biochemical autoantibodies (ICA-512, GAD 65 or             IAA) prior to enrolling#        Exclusion Criteria:#          -  Previous treatment with an anti-IL-2 directed monoclonal antibody or any other             investigational agent that would interfere with the ability to evaluate the safety             and efficacy of daclizumab.#          -  Other immunosuppressive drugs including, but not limited to, corticosteroids,             cyclosporine, tacrolimus, rapamycin, mycophenolate mofetil, or azathioprine.#          -  Active significant infection#          -  Limited life expectancy because of disease other than diabetes#          -  Pregnancy","both","2 years","40 years"
"NCT00206258","Inclusion Criteria:#          1. Age >12 years < 19 years#          2. Have diabetes for at least 2 years and in good control (HbA1C < 8%).#          3. Be on continuous subcutaneous insulin infusion using an insulin pump.#          4. Subjects must be otherwise healthy except for their T1DM and treated for             hypothyroidism.#          5. Menstruating women must have negative pregnancy test.#          6. Hemoglobin equal to or > than 12 g/dL before each study.#          7. Weight more than 44 kg.#        Exclusion Criteria:#          1. Age >18 or < 12 y at the time of study#          2. Any chronic disease (leukemia, asthma, inflammatory bowel disease, cystic fibrosis,             juvenile rheumatoid arthritis, etc that directly, or as a result of treatment,             directly or indirectly affect glucose homeostasis#          3. Hemoglobin less than 12 g/dl (If before any of the studies the hemoglobin is lower             than 12 g/dl, subjects will be excluded from further studies)#          4. Lack of a supportive family environment#          5. Positive pregnancy test in menstruating young women#          6. Evidence or history of chemical abuse#          7. Hgb A1c >8.0 % in a diabetic subject#          8. BMI > 90 % tile for age or < 10 % tile for age#          9. Allergy to local anesthetics (ELAMAX Cream)#         10. Weight less than 44 kg#         11. Children of staff members","both","12 years","21 years"
"NCT00206297","Inclusion Criteria:#        Twenty (20) children with T1DM will be recruited for these studies. These children will be        subjects of the Texas Children's Hospital Diabetes Care Center. The subjects must be:#          1. Between 12-21 years of age at the time of enrollment.#          2. Have been diagnosed with diabetes for at least 2 years and in good control (HbA1C             less than 8.5%).#          3. Be on continuous subcutaneous insulin infusion using an insulin pump.#          4. Subjects must be otherwise healthy except for their T1DM and treated hypothyroidism.#          5. Menstruating women must have a negative pregnancy test.#          6. Hemoglobin equal to or > 12 g/dL before each study.#          7. Weight more than 44 kg. -#        Exclusion Criteria:#          1. Age greater than 22 years or less than 12 years at the time of study#          2. Any chronic disease: leukemia, asthma, inflammatory bowel disease, cystic fibrosis,             juvenile rheumatoid arthritis, etc or on treatment that might directly or indirectly             affect glucose homeostasis, except for diabetes and hypothyroidism stable on             medications#          3. Anemia (hemoglobin less than 12mg/dl)#          4. Lack of a supportive family environment#          5. Positive pregnancy test in menstruating young women#          6. Evidence or history of chemical abuse#          7. Hgb A1C greater than or equal to 8.5 % in a diabetic subject#          8. BMI > 90 % tile for age or < 10 % tile for age#          9. Weight less than 44 kg. -","both","12 years","21 years"
"NCT00206401","Inclusion Criteria:#          -  Age greater than 6 years of age but less than 25 years of age (Insulin glargine has             been approved for use in children 6 years and older).#          -  Patients newly diagnosed with T1DM within the past 3 months.#          -  Have an HgbA1c of less than 9.0%, after the initial run-in period of 3 months.#          -  Have a BMI of less than the 90th percentile for age.#          -  Randomization of subjects willing to participate in the study.#        Exclusion Criteria:#          -  Any chronic disease (leukemia, asthma, inflammatory bowel disease, cystic fibrosis,             juvenile rheumatoid arthritis, etc) that directly, or as a result of treatment,             directly or indirectly affect glucose homeostasis.#          -  Lack of supportive family.#          -  Evidence or history of chemical abuse.#          -  Age less than 6 years or greater than 25 years.#          -  HbA1c level of greater than 9.0%, after the initial run-in period of 3 months.#          -  Have a BMI greater than the 90th percentile for age.#          -  Patients who are not newly diagnosed with T1DM.","both","6 years","25 years"
"NCT00211510","Inclusion Criteria:#          -  Age 12 - 80 years#          -  Type 1 Diabetes Mellitus diagnosed at least 1 year ago#          -  Using insulin infusion pump for past 6 months minimum#          -  Performing minimum 4 blood glucose tests per day#          -  Agree to treat to A1c targets#          -  Read and understand English#        Exclusion Criteria:#          -  Pregnant or planning pregnancy#          -  History of unresolved tape allergy or skin conditions","both","12 years","80 years"
"NCT00211536","-  Type 1 diabetes mellitus (American Diabetes Association definition)#          -  HbA1c greater than or equal to 7.5%#          -  Intensive insulin treatment for at least 3 months#          -  Physical and intellectual ability to operate MIP system#          -  Subject has been under the routine care of the investigator for at least two months             prior to enrollment#          -  Subject has a reliable support person (defined as a person who has daily contact with             the subject and knows whom to contact in the event of an emergency).#          -  Capability and willingness to perform self-monitoring of blood glucose at least four             times daily for 9 months of the study and 7 times daily for 3 months of the study#          -  Physical and intellectual ability to operate the MIP system and to comply with the             data reporting requirements of the study.#          -  Subject is willing to sign the informed consent form (approved by local Institutional             Review Board and Medtronic MiniMed)#        Exclusion Criteria:#          -  The subject's insulin usage exceeds 66 units per day.#          -  Severe complications such as advanced autonomic neuropathy, legal blindness, or             symptomatic cardiovascular disease as evidenced by a cardiovascular episode within             the last six months#          -  Reside at or plan to travel to elevations above 8000 feet during the study period             (commercial airline travel is acceptable)#          -  Subject who is pregnant, of childbearing potential or lactating and is neither             surgically sterile, using contraceptives (devices, oral or implanted) nor other             physician approved contraceptive#          -  The subject has any major concomitant disease or any physical or psychological             disorder within the last five years, which might be considered life threatening, or             which might confound the collection or interpretation of the study data#          -  The subject has previously enrolled in or participated in an investigational drug or             device study within the preceding 4 weeks#          -  The subject has any condition that precludes him/her from completing the study             requirements#          -  Has plans for activities which require them to go 25 feet below sea level","both","18 years","65 years"
"NCT00212329","Inclusion Criteria:#        To be eligible, individuals with type 1 diabetes must be:#          -  Diagnosed with type 1 diabetes within one year of first study visit#          -  8-35 years of age at time of first visit#          -  Weigh > 40 kg (88 lbs) at time of first visit#          -  Individuals who will serve as control subjects who do not have type 1 diabetes cannot             have a first degree or second degree relative with type 1 diabetes.#        Exclusion Criteria:#        Individuals must not:#          -  Have any major illness#          -  Be taking any steroid medications#          -  If female, should not be pregnant or breastfeeding.","both","8 years","35 years"
"NCT00213109","Inclusion Criteria:#          -  Type1 Diabetes#          -  Criteria of postprandial glucose and HbA1c are met#        Exclusion Criteria:#          -  Type2 Diabetes#          -  Patients with antidiabetic drugs#          -  The other exclusion criteria are met","both","20 years",""
"NCT00214214","Inclusion Criteria:#          -  Adult subjects ages 18-35, with new onset type 1 diabetes mellitus (within 2-12 weeks             of diagnosis), one or more islet autoantibody to GAD, IA2, IAA or islet cell             cytoplasmic antibody (ICA) within 2 weeks of diabetes diagnosis.#        Exclusion Criteria:#          -  Subjects under 18 years of age or over 35 years of age.#          -  Subjects who have previously received an organ transplant.#          -  Subjects who are currently receiving systemic corticosteroids for other medical             diseases in which the physician feels discontinuation of corticosteroids is             contraindicated.#          -  Subjects with a history of other medical condition(s) known to affect blood glucose             values (i.e., Cushing's disease, acromegaly).#          -  Subjects with a history of other chronic systemic inflammatory or autoimmune disease             or other severe medical condition. (A history of treated hypothyroidism with             documentation of normal serum thyroid hormone levels will not be exclusionary.)#          -  Patients with a history of hepatitis B, hepatitis C, or HIV.#          -  PPD positive at the time of evaluation.#          -  Thrombocytopenia or neutropenia. Individuals will be considered to have             thrombocytopenia if they have a platelet count <100,000 platelets/mm2 or <3,000             WBC/ml.#          -  Subjects with a history of renal, pulmonary, or cardiac failure#          -  Subjects with severe systemic infections. Only those subjects who have completed             treatment and have shown a complete clinical resolution will be considered eligible             for the study.","both","18 years","35 years"
"NCT00214253","Inclusion Criteria:#          -  16 Type I insulin-dependent diabetic subjects ages 18-60,(8 who have received a prior             kidney or liver transplant and have stable renal function, and 8 who have labile             glucose regulation and who have failed a trial of intensive exogenous insulin therapy             and who have preserved native renal function)#        Exclusion Criteria:#          -  untreated proliferative diabetic retinopathy;#          -  HgbA1C >12%; creatinine clearance < 80 ml/minute or macroalbuminuria > 0.3 gm/24 hrs;#          -  presence of panel reactive antibodies >20%","both","18 years","65 years"
"NCT00223613","Inclusion Criteria:#          -  children carrying HLA-conferred genetic risk for developing type 1 diabetes#          -  have had at least two types of autoantibodies of ICA, IAA, GADA and IA-2A in at least             two consecutive blood samples drawn at least 3 months apart#          -  age at least one year#        Exclusion Criteria:#          -  severe other disease#          -  age above 15 years","both","1 year","15 years"
"NCT00226902","Inclusion Criteria:#          1. Aged 18-80 years#          2. Patients receiving either conventional haemodialysis 3-4 x week, for a duration of >             6 months or peritoneal dialysis for a duration >6 months#          3. Stable dialysis access for at least 3 months (Permcath / PTFE / AVF)#          4. On erythropoietin and iron therapy, with stable [Hb] x 2 months (105 - 135g/L)#        Exclusion Criteria:#          1. Uncontrolled BP: requiring dry weight or medication changes within 4 weeks prior to             study#          2. Patients with dysrhythmias#          3. Pre dialysis SBP> 180 mmHg on > 2 times within a 2 week period#          4. Between dialysis weight gain > 5% of body weight (if evident > 2 times/ 2 week             period)#          5. Soft tissue ulcers#          6. Non traumatic amputations#          7. Unstable cardiac function: ischaemic or non ischaemic events requiring modification             of therapy, or admission to hospital within 3 months of study start: according to             clinical discretion#          8. Planned operative procedures within 6 months of study start (including Transplant,             CABG, PTCA, vascular surgery)#          9. Dementia#         10. Clinical inability to comply with testing#         11. Malignancy (active / under treatment)#         12. Known hypo-responsiveness to ERT (>200U/kg/wk)#         13. Evidence of chronic gastrointestinal bleeding#         14. Inadequate dialysis (PRU < 65% or KT/V < 1.2)#         15. Participation in investigational study within last 3 months","both","18 years","80 years"
"NCT00229658","Inclusion Criteria:#          -  The following inclusion criteria are consistent with information in the SYMLIN             package insert and apply to insulin using patients with type 2 or type 1 diabetes             who:#               -  Have failed to achieve the desired or optimal level of glycemic control despite                  utilizing appropriate, individualized insulin regimens#               -  Have A1C <=9.0% within 3 months of study enrollment#               -  Are receiving ongoing diabetes care under the guidance of a Health Care Provider                  (HCP) trained in the use of SYMLIN#        Exclusion Criteria:#          -  The following exclusion criteria are consistent with the SYMLIN package insert and             specifically exclude patients who:#               -  Are poorly compliant with their current insulin regimen, as defined by their HCP#               -  Are poorly compliant with prescribed blood glucose self monitoring, as defined                  by their HCP#               -  Have experienced recurrent patient-ascertained severe hypoglycemia requiring                  assistance during the past 6 months#               -  Have hypoglycemia unawareness#               -  Have a confirmed diagnosis of gastroparesis#               -  Require the use of drugs that stimulate gastrointestinal motility#               -  Are female and pregnant or lactating and for whom the HCP determines the                  potential benefit does not justify the potential risk to the fetus or infant#               -  Have been treated with SYMLIN within 3 months prior to study start","both","18 years",""
"NCT00239148","Inclusion Criteria:#          -  Clinical diagnosis Type 1 diabetes requiring treatment with insulin for a minimum of             1 year#          -  On a stable insulin regimen for at least 60 days prior to screening#          -  Currently self monitoring blood glucose levels at least 3 times per day#          -  No episodes of severe hypoglycemia for 60 days prior to screening#          -  Body mass index within the range 19-30 kg/m2#          -  Patient cannot live alone during the treatment phase and up to 1 month in follow-up#        Exclusion Criteria:#          -  Known of suspected history of significant liver, or other GI disease#          -  History of significant cardiovascular disease including stroke, peripheral vascular             disease or any related symptoms#          -  History of peptic ulcer disease and/or GI bleeding/perforation#          -  History of cancer#          -  History or presence of proliferative retinopathy, severe non-proliferative             retinopathy, macular edema or presence of untreated diabetic eye disease#          -  History of treated peripheral or autonomic neuropathy#          -  Serum creatine superior or equal to 2.0 mg/dL#          -  History of hypoglycemia unawareness#          -  Non-healed diabetic ulcer","both","18 years","40 years"
"NCT00252720","Inclusion Criteria:#          -  Male or female aged 18 - 55 years with type 1 diabetes diagnosed before age of 36             years  and in need for continuous insulin treatment within 1 year of diagnosis of             diabetes are included.#          -  Duration of diabetes for > 1 year and < 20 years with stable diabetic therapy within             last 6 months.#          -  Patients with untreated resting mean sitting SBP < 130 mmHg, mean sitting DBP < 85             mmHg and with retinal photograph grading level > 20/10 up to < 47/47 (on ETDRS             severity scale).#        Exclusion Criteria:#          -  Patients with the following conditions are excluded from participation on the study:#          -  Cataract or media opacity of a degree which precludes taking gradable retinal             photographs#          -  Angle closure glaucoma, which precludes pharmacological dilatation of the pupil#          -  History or presence of proliferative retinopathy#          -  History or presence of clinical significant macular oedema (CSME)#          -  History or evidence of photocoagulation of the retina#          -  Other retinal conditions which may mask assessment, eg, retinal vein occlusion#          -  Positive micral dipstick test#          -  Presence of secondary diabetes#          -  Pregnant or lactating women or women of child bearing potential not practicing an             adequate method of contraception#          -  Need of treatment with ACE-inhibitor#          -  Haemodynamically significant aortic or mitral valve stenosis#          -  Known renal artery stenosis or kidney transplantation#          -  Hypersensitivity to study drug#          -  Severe concomitant disease which may interfere with the assessment of the patient,             eg, malignancy, as judged by the investigator","both","18 years","55 years"
"NCT00252733","Inclusion Criteria:#          -  Type 1 diabetes diagnosed before age of 36 years and in need for continuous insulin             treatment within 1 year of diagnosis of diabetes are included.#          -  Duration of diabetes for > 1 year and < 15 years with stable diabetic therapy within             last 6 months.#          -  Patients with untreated resting mean sitting SBP < 130 mmHg, mean sitting DBP < 85             mmHg and with retinal photograph grading level 10/10 (on ETDRS severity scale).#        Exclusion Criteria:#          -  Patients with the following conditions are excluded from participation in the study:#          -  Cataract or media opacity of a degree which precludes taking gradable retinal             photographs#          -  Angle closure glaucoma, which precludes pharmacological dilatation of the pupil#          -  History of retinopathy#          -  History or presence of clinical significant macular oedema (CSME)#          -  History or evidence of photocoagulation of the retina Other retinal conditions which             may mask assessment, eg, retinal vein occlusion#          -  Positive micral dipstick test#          -  Presence of secondary diabetes#          -  Pregnant or lactating women or women of child bearing potential not practicing an             adequate method of contraception#          -  Need of treatment with ACE-inhibitor#          -  Haemodynamically significant aortic or mitral valve stenosis#          -  Known renal artery stenosis or kidney transplantation#          -  Hypersensitivity to study drug#          -  Severe concomitant disease which may interfere with the assessment of the patient,             eg, malignancy, as judged by the investigator","both","18 years","50 years"
"NCT00254501","Inclusion Criteria:#          -  diabetes (Type I or Type II)#          -  enrolled in health plan with participating employer#          -  age 18 or older#          -  willing and able to provide informed consent#        Exclusion Criteria:#          -  gestational diabetes","both","18 years",""
"NCT00260234","Inclusion Criteria:#          -  Male or non-pregnant non-lactating female subjects > 20 years of age#          -  Diagnosed with insulin-dependent type I diabetes for at least 20 years#          -  BMI less than 28 kg/m2#          -  Insulin requirement less than or equal to 0.7 U/kg/day#          -  HbA1c greater than or equal to 7.0 %#          -  Serum C-peptide concentration less than or equal to 0.5 ng/mL stimulated by an OGTT#          -  Female subjects with childbearing potential must have a negative serum pregnancy test             prior to enrollment and must agree to use an effective contraceptive method during             the study#          -  One year of stable diabetes care established in the PI's database without significant             changes in insulin requirement or HbA1c or diabetic complication profile#        Exclusion Criteria:#          -  Diagnosis of type II diabetes or maturity onset diabetes of youth (MODY)#          -  Serum C-peptide greater than 0.5 ng/mL stimulated by OGTT#          -  Sustained hypertension greater than or equal to 100 mmHg diastolic and/or greater             than or equal to 160 mmHg systolic#          -  History of myocardial infarction or current active cardiac disease#          -  Current active infection#          -  Significant renal dysfunction as indicated by GFR less than 80 mL/min/1.73 m2  and/or             urinary albumin greater than 500 µg/mL#          -  Significant liver dysfunction as indicated by ALT or AST more than 3X the upper limit             of normal#          -  Prior whole organ or islet cell transplant#          -  Concurrent immunosuppressive therapy#          -  Severe gastroparesis, severe peripheral neuropathy, diabetic foot ulcers, or prior             amputations due to diabetic complications#          -  Any other active autoimmune disease other than autoimmune thyroid disease#          -  HIV, HBV or HCV positive status#          -  Uncontrolled or untreated proliferative retinopathy#          -  Known hypersensitivity or other intolerance to cyclosporine or the inactive             ingredients in the product#          -  Behavioral activities that place the subject at risk in the opinion of the             investigator#          -  Any significant concurrent disease, illness, or psychiatric disorder that would, in             the opinion of the investigator, compromise subject safety or compliance, or             interfere with consent, study participation, follow-up, or the interpretation of             study results#          -  History of any kind of cancer other than skin cancers (except for melanoma which is             exclusionary)","both","20 years",""
"NCT00265473","Inclusion Criteria:#          1. Age 18 to 65 years of age.#          2. Ability to provide written informed consent.#          3. Mentally stable and able to comply with the procedures of the study.#          4. Clinical history compatible with type 1 diabetes with onset of disease at <40 years             of age and insulin-dependence for > 5 years at the time of enrollment.#          5. Absent stimulated C-peptide (<0.3ng/ml) in response to a mixed meal tolerance test.#          6. Involvement in intensive diabetes management defined as self monitoring of glucose             values no less than a mean of three times each day averaged over each week and by the             administration of three or more insulin injections each day or insulin pump therapy.             Such management must be under the direction of an endocrinologist, diabetologist, or             diabetes specialist with at least 3 clinical evaluations during the previous 12             months.#          7. At least one episode of severe hypoglycemia in the past 3 years defined as an event             with symptoms compatible with hypoglycemia in which the subject required the             assistance of another person and which was associated with either a blood glucose             level < 50 mg/dl or prompt recovery after oral carbohydrate, intravenous glucose, or             glucagon administration).#          8. Reduced awareness of hypoglycemia.#        Exclusion Criteria:#          1. Any previous transplant.#          2. BMI >27 kg/m2 or patient weight <= 50kg.#          3. Insulin requirement of > 0.8 IU/kg/day or 50 IU/day.#          4. HbA1c >10%.#          5. Untreated proliferative diabetic retinopathy.#          6. Uncontrolled Hypertension.#          7. Estimated glomerular filtration rate <70 ml/min/1.73 m2 for females and <80             ml/min/1.73 m2 for males#          8. Presence or history of macroalbuminuria (>300mg/d).#          9. Presence or history of panel-reactive anti-HLA antibodies >20% by flow cytometry.#         10. Females:  Positive pregnancy test, presently breast-feeding, or unwillingness to use             effective contraceptive measures for the duration of the study and 3 months after             discontinuation.  Males:  intent to procreate during the duration of the study or             within 3 months after discontinuation or unwillingness to use effective measures of             contraception.#         11. Active infection.#         12. Negative screen for Epstein-Barr Virus (EBV).#         13. Invasive aspergillus infection within one year prior to study entry.#         14. Any history of malignancy except for completely resected squamous or basal cell             carcinoma of the skin.#         15. Active alcohol, tobacco or substance abuse.#         16. Baseline Hgb below the lower limits of normal at the local laboratory; lymphopenia,             neutropenia, or thrombocytopenia.#         17. A history of Factor V deficiency.#         18. Any coagulopathy or medical condition requiring long-term anticoagulant  therapy.#         19. Severe co-existing cardiac disease.#         20. Persistent elevation of liver function tests.#         21. Symptomatic cholecystolithiasis.#         22. Acute or chronic pancreatitis.#         23. Symptomatic peptic ulcer disease.#         24. Unremitting diarrhea, vomiting or other gastrointestinal disorders potentially             interfering with absorption.#         25. Hyperlipidemia despite medical therapy (fasting LDL cholesterol > 130 mg/dl, treated             or untreated; and/or fasting triglycerides > 200 mg/dl).#         26. Chronic use of systemic steroids.#         27. Use of any other investigational agents within 4 weeks of participation.#         28. Administration of live attenuated vaccine(s) within 2 months of enrollment.#         29. Any medical condition that, in the opinion of the investigator, will interfere with             the safe completion of the trial.","both","18 years","65 years"
"NCT00271284","Inclusion Criteria :#          -  Belonging to a social security scheme or covered by such a scheme#          -  With type 1 diabetes (defined as a concentration of C-peptide < 0.1 nmol//l and a             fasting blood glucose of >= 1.26 g/l), diagnosed not less than 5 years previously#          -  Treated for at least 6 months by intensive insulin treatment, following a basal-bolus             system, using insulin glargine (Lantus®) as basal insulin. During the study, this             insulin will administered in the evening#          -  Trained in the titration of prandial insulin (the dose of rapid insulin decided at             each mealtime depending on the composition of the meal)#          -  With an HbA1c level of <= 8.5% at the inclusion visit#          -  Capable of checking their blood glucose concentration using the material supplied by             the sponsor: blood glucose meter and patient notebook#          -  Able to eat 3 regular daily meals on the days for recording the blood glucose cycle             and similarly as much as possible on other days throughout the length of the study#          -  Able to continue their usual daily activities during the study#          -  Women of child-bearing potential should be using an effective method of contraception#          -  Fundal examination result less than a year old available#        Exclusion Criteria:#          -  Recent history of severe hypoglycaemia (at least 2 events in the 6 months prior to             inclusion)#          -  An episode of acidocetosis in the 3 months prior to inclusion#          -  Proliferating retinopathy, defined as having required treatment by surgery or             photocoagulation, in the 6 months prior to visit 1, or non-stabilised (rapidly             developing) retinopathy which may require photocoagulation or surgery#          -  Pancreatectomy#          -  Altered hepatic function (AST or ALT >= 2.5 x normal, in the initial measurements)#          -  Altered renal function (plasma creatinine > 1.5 mg/dl)#          -  Acute infection#          -  Acute or chronic metabolic acidosis#          -  Gastroparesis#          -  History of cancer in the last 5 years#          -  Medically significant cardiovascular, hepatic, neurological or endocrine disease or             any other significant disease making carrying out the protocol or interpreting the             trial results difficult#          -  History of drug or alcohol abuse#          -  Subject likely to receive treatment during the trial which is not authorised in the             protocol (see Section 6.2), in particular, treatment by corticosteroids whatever the             route of administration or dose.#          -  Antidiabetic treatment by products other than those supplied within the framework of             this study#          -  Treatment by another product undergoing development during the 3 months prior to             inclusion in the trial#          -  Hypersensitivity to one of the study products (insulin glargine, insulin detemir,             insulin glulisine) or to one of the excipients present in the insulin preparations,             used in the study#          -  Working at night#          -  Pregnancy#          -  Breast-feeding#          -  Mental state making the subject incapable of understanding the objectives and             possible consequences of the trial#          -  Subject unable to submit to the restrictions of the protocol (e.g. uncooperative,             incapable of attending monitoring visits and probably incapable of finishing the             trial)#          -  Subject deprived of his liberty because of an administrative or legal decision#          -  The investigator or any member of the team or close to the investigator directly             implicated in the trial particularly assistant doctors, pharmacists, nurses, trial             coordinator, etc.#        The above information is not intended to contain all considerations relevant to a        patient's potential participation in a clinical trial.","both","18 years",""
"NCT00272090","Inclusion criteria:#          -  Subjects with type 1 diabetes mellitus for more than three years#          -  Subjects on multiple daily injection insulin therapy, basal-bolus scheme therapy#          -  HbA1c <= 9 % (measured by central Lab, with DCCT aligned standard method)#          -  Fasting C-Peptide <= 0,1nmol/L with FBG >126 mg/dl#          -  Body Mass Index (BMI) < 30 kg/m2#          -  Willingness to accept intensive insulin therapy#          -  Ability and willingness to perform SMBG using plasma glucose meter#          -  Female subjects must be postmenopausal or under adequate contraception as judged by             the investigator (it may be oral contraceptives, intra-uterine device or surgical             treatment) and must have a negative serum pregnancy test#        Exclusion criteria:#          -  Diabetes other than type 1 diabetic mellitus#          -  Type 1 diabetic patients with total insulin dose >= 1 IU/kg/day#          -  Serum creatinine > 1.5 mg/dl, or history of renal transplantation or current renal             dialysis#          -  Congestive heart failure NYHA class II#          -  Acute or chronic metabolic acidosis, including diabetic ketoacidosis#          -  Clinical evidence of active liver disease, or serum ALT/AST  2 times the upper limit             of the normal range#          -  Hypoglycemia unawareness#          -  Pregnancy or lactation#          -  Concomitant use of β-blockers, thiazides or systemic corticosteroids#          -  More than one episode of severe hypoglycemia with seizure or coma during the past             year#          -  Likelihood of requiring treatment during the study period with any anti-diabetic drug             other than the study drugs#          -  Failure to use adequate contraception (women of current reproductive potential only)#          -  Known hypersensitivity to insulin glargine, or any of the excipients#          -  Malignancy except basal cell carcinoma within the last five years#          -  Long lasting (> 2 weeks) treatment with systemic glucocorticoid therapy#          -  Known adrenal insufficiency (interferes with hypoglycemia counter-regulation)#          -  Known hemoglobinopathy or chronic anemia because it may interfere with Hb1Ac             determination#          -  History of substance or alcohol abuse within the last two years or current addiction             to substances of abuse including ethanol#          -  History of positive HIV test or Hepatitis B/C test#          -  Any usage outside of the current SPC (Summary of the Product Characteristics)#          -  Any clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other             major systemic disease other than type 1 diabetic mellitus making implementation of             the protocol or interpretation of the study results difficult#          -  History of demonstrable micro- and macro-angiopathic complications#          -  Pre-planned surgery during the study#          -  Blood donation of more than 500 ml during the previous 3 months for males or 6 months             for females#          -  Smoker for previous 3 months#          -  Receipt of an experimental drug or use of an experimental device within the 30 days             prior to study entry.","both","18 years","60 years"
"NCT00273286","Child Inclusion Criteria:#          -  Age 9.0 to <14.5.#          -  Type 1 diabetes diagnosis (diagnosed by ADA criteria) for a minimum of 1 year for the             main subgroup or 3 months for the recent onset subgroup.#          -  Insulin dose greater than or equal to 0.5 u/kg/day for the main subgroup or 0.2             u/kg/day for the recent onset subgroup; with 2 or more daily injections or use of             insulin pump.#          -  Most recent A1c is >6.0% and <13.0%; <12.0% for those diagnosed for less than 1 year.#          -  Willing to provide informed assent.#        Parent/Family Environment Inclusion Criteria#          -  Child lives in geographically stable home, no multiple foster homes, boarding school,             or institutions expected in next 2 years.#          -  The same 1 or 2 adult caregivers have accompanied the child to every diabetes clinic             visit in the past year, and at least 1 caregiver agrees to participate in all aspects             of the protocol (single-parent families, blended families, and separated parents will             be eligible).#          -  Home has telephone access.#          -  Child had at least 2 clinic visits within last 12 months.#          -  Parent and child willing to come to clinic every 3 months for duration (2 years) of             study.#          -  If a family has more than one eligible child, all qualifying children who provide             consent/assent will participate in assessment and intervention or control activities;             however, only the oldest qualifying child will be included in statistical analyses.#        Child Exclusion Criteria:#          -  Presence of a major chronic diseases (except well-controlled thyroid, asthma,             celiac).#          -  Presence of a major visual/auditory impairments.#          -  Child is in a self-contained special education class throughout the school day.#          -  Record of inpatient hospitalization for mental disorder in past six months including             substance abuse rehabilitation, eating disorder units or day treatment programs.             Current diagnosis of eating disorder.  History of anti-psychotic medications for the             past 6 months.#          -  Diagnosis of mental retardation.#          -  Unable to read and write English at 2nd grade level.#          -  Children who are currently enrolled in any intervention study are not eligible for             enrollment. Those who have been in an intervention arm of a trial of a behavioral,             psychological or psychoeducational intervention and concluded their study follow-up             within the past 12 months are also ineligible to participate.  However, children who             were in a standard care control group in an intervention study are eligible once they             have completed all scheduled study follow-ups.  Children cannot enroll in another             intervention study during the course of this study. Enrollment of children who are             currently participating in another observational study will be at the discretion of             the site principal investigator.#        Parent/Family Environment Exclusion Criteria#          -  Family has plans to re-locate out of area within the next 2 years of the study.#          -  Participating caretaker is currently undergoing treatment for substance abuse.#          -  Participating caretaker has been hospitalized in past 6 months for mental disorder.#          -  Participating caretaker has history of psychosis.#          -  Families who are currently enrolled in any intervention study are not eligible for             enrollment. Those who have been in an intervention arm of a trial of a behavioral,             psychological or psychoeducational intervention and concluded their study follow-up             within the past 12 months are also ineligible to participate.  However, families who             were in a standard care control group in an intervention study are eligible once they             have completed all scheduled study follow-ups.  Families cannot enroll in another             intervention study during the course of this study. Enrollment of families who are             currently participating in another observational study will be at the discretion of             the site principal investigator.#        The family must reside within 90 miles (one-way) of the clinic (main or satellite), or        agree to meet at a mutually agreed upon closer location for conduct of the home        assessment.","both","108 months","174 months"
"NCT00276250","Inclusion Criteria:#          -  Male and Female patients age 18 to 65 years of age#          -  Clinical history compatible with type 1 diabetes with onset of disease at <40 years             of age and insulin-dependence for >5 years at the time of enrollment.#          -  Body mass index less than or equal to 26#          -  18 to 65 years of age#          -  Absent stimulated C-peptide (<0.3ng/ml) in response to a mixed meal tolerance test             (Boost® 6 mL/kg body weight to a maximum of 360 mL; another product with equivalent             caloric and nutrient content may be substituted for Boost)  measured at 90min after             the end of consumption.#          -  Compliance with an optimized diabetic management plan as assessed by an Emory             University endocrinologist#          -  Checking and recording blood sugars at least 3 times per day#          -  Involvement in intensive diabetes management defined as self monitoring of glucose             values no less than a mean of three times each day averaged over each week and by the             administration of three or more insulin injections each day or insulin pump therapy.             Such management must be under the direction of an endocrinologist, diabetologist, or             diabetes specialist with at least 3 clinical evaluations during the previous 12             months.#          -  At least one episode of severe hypoglycemia in the past 3 years defined as an event             with symptoms compatible with hypoglycemia in which the subject required the             assistance of another person and which was associated with either a blood glucose             level <50 mg/dL [2.8 mmol/L] or prompt recovery after oral carbohydrate, intravenous             glucose, or glucagon administration).#          -  Reduced awareness of hypoglycemia as defined by a Clarke score of 4 or more and a             HYPO score greater than or equal to the 90th percentile (1047) within the last 6             months prior to randomization; OR Marked glycemic lability characterized by wide             swings in blood glucose despite optimal diabetes therapy and defined by a glycemic             lability index (LI) score greater than or equal to the 90th percentile (433 mM2/h/wk)             within the last 6 months prior to randomization; OR A composite of a Clarke score of             4 or more and a HYPO score greater than or equal to the 75th percentile (423) and a             LI greater than of equal to the 75th percentile (329) within the last 6 months prior             to randomization.#        Exclusion Criteria:#          -  Severe co-existing cardiac disease, characterized by any one of these conditions:#          -  Recent myocardial infarction (within past six months)#          -  Left Ventricular Ejection Fraction < 30%#          -  Evidence of ischemia on a functional echocardiogram#          -  Active infection including hepatitis B, hepatitis C, HIV, or TB as determined by a             positive skin test or clinical presentation, or under treatment for suspected TB.             Positive tests are acceptable only if associated with a history of previous             vaccination in the absence of any sign of active infection. Positive tests are             otherwise not acceptable, even in the absence of any active infection at the time of             evaluation#          -  Invasive aspergillus infection within one year prior to study entry.#          -  Negative screen for Epstein-Barr Virus (EBV) by IgG determination.#          -  Administration of live vaccine within the past two months#          -  Measured glomerular filtration rate using iohexol <70 mL/min/1.73 m2 for females and             <80 mL/min/1.73 m2 for males (or a 24 hr. creatinine clearance with participants             allergic to iodine <85mL/min/1.73m2).#          -  Macroalbuminuria (urinary protein excretion rate >300 mg/24h)#          -  Baseline Hgb below the lower limits of normal at the local laboratory; lymphopenia             (<1,000/L), neutropenia (<1,500/L), or thrombocytopenia (platelets <100,000/ L).#          -  Hyperlipidemia (fasting LDL cholesterol >130 mg/dL, treated or untreated; and/or             fasting triglycerides >300 mg/dL)#          -  Negative antibody test for Varicella zoster virus (subjects may be reconsidered if             they receive the vaccination and convert to a positive antibody)#          -  History of malignancy (except squamous or basal cell skin carcinoma) within the             previous 5 years#          -  Previous/concurrent organ transplantation#          -  Presence of HLA Panel Reactive Antibodies >20%#          -  Active peptic ulcer disease#          -  Evidence of gallbladder disease including cholecystitis and cholelithiasis#          -  Evidence of liver disease including: hepatic neoplasm, portal hypertension, or             persistently abnormal liver function tests#          -  Current use of systemic steroid medications#          -  Evidence of insulin resistance (insulin requirements >0.8 units/kg/day)#          -  Inability to provide informed consent#          -  Severe unremitting diarrhea, vomiting or other gastrointestinal disorders potentially             interfering with the ability to absorb oral medications.#          -  Hyperlipidemia despite medical therapy (fasting LDL cholesterol >130 mg/dL, treated             or untreated; and/or fasting triglycerides >200 mg/dL).#          -  Acute or chronic pancreatitis.#          -  Symptomatic peptic ulcer disease.#          -  Use of any other investigational agents within 4 weeks of participation.#          -  Any condition or any circumstance that makes it unsafe to undergo an islet cell             transplant#          -  Any coagulopathy or medical condition requiring long-term anticoagulant  therapy             (e.g., warfarin) after transplantation (low-dose aspirin treatment is allowed) or             patients with an INR >1.5.#          -  Sickle Cell Anemia (Subjects with Sickle Cell Anemia, trait HbSS, are at high risk             for complications after transplantation related to immunosuppressive therapy.  These             complications include stroke and sickle cell crisis.  Therefore, we will exclude             these subjects from our study to minimize risks to study subjects.)#          -  For female participants:  Positive pregnancy test, presently breast-feeding, or             unwillingness to use effective contraceptive measures for the duration of the study             and 3 months after discontinuation.  For male participants:  intent to procreate             during the duration of the study or within 3 months after discontinuation or             unwillingness to use effective measures of contraception.  Oral contraceptives,             Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable             contraceptive methods; condoms used alone are not acceptable.#          -  Active alcohol or substance abuse.  This includes cigarette smoking (must be             abstinent for six months).  Active alcohol abuse should be considered using the             current NIAAA definitions, whereby alcohol abuse is defined by a pattern of drinking             that is accompanied by one or more of the following situations within a 12-month             period:#          -  Failure to fulfill major work, school, or home responsibilities#          -  Drinking in situations that are physically dangerous, such as while driving a car or             operating machinery#          -  Recurring alcohol-related legal problems, such as driving under the influence of             alcohol or for causing physical harm to someone while intoxicated#          -  Continued alcohol abuse despite having ongoing relationship problems that are caused             or worsened by the effects of alcohol#          -  Psychiatric disorder making the subject not a suitable candidate for transplantation,             e.g., schizophrenia, bipolar disorder, or major depression that is unstable or             uncontrolled on current medication.  (A psychological or psychiatric consultation is             required only if considered necessary by some current indication or history.)","both","18 years","65 years"
"NCT00276393","Type 1 diabetes, HbA1c < 7.8%, who have had prior instruction in a complex insulin        program, and presently using a MDI insulin program with basal insulin preparations of        Glargine or Ultralente and Humalog as the short acting insulin, should be free of        hepatorenal abnormalities and hypoglycemia unawareness; non-pregnant, and should be able        to perform frequent self monitoring of blood glucose (SMBG) and accept the use of        continuous glucose monitoring system (CGMS). They should also possess the skill and        understanding of insulin dose adjustments and supplementation.","both","18 years","80 years"
"NCT00278980","Inclusion Criteria:#          -  Subjects who have a duration of type 1 diabetes of more than 5 yrs#          -  Subjects who are C-peptide deficient#          -  Subjects who have diabetic distal symmetric neuropathy, according to the criteria             defined at the San Antonio Conference on Diabetic Neuropathy 1988#          -  Subjects who have measurable action potential in the sural nerves#          -  Subjects who have reduced nerve conduction velocity in the sural nerves#        Exclusion Criteria:#          -  Subjects who have neuropathy or signs of nerve dysfunction which may be a consequence             of factors other than type 1 diabetes#          -  Subjects who have concomitant medication that may interfere with the peripheral nerve             function or measurement thereof#          -  Subjects who are transplanted (islet cell, kidney or pancreas)","both","18 years","55 years"
"NCT00279305","Inclusion Criteria:#          -  Between the ages of 8 and 45 years#          -  Within 3 months of diagnosis of type 1 diabetes#          -  Have presence of at least one diabetes-related autoantibody#          -  Must have stimulated C-peptide levels of at least 0.2 pmol/ml measured during a mixed             meal tolerance test (MMTT) within one month of randomization#          -  If female with reproductive potential, willing to avoid pregnancy and undergo             pregnancy testing while participating in the study#          -  Have not received an immunization for at least one month#          -  Must be willing to comply with intensive diabetes management#          -  Must weigh at least 25 kg at study entry#        Exclusion Criteria:#          -  Are immunodeficient or have clinically significant chronic lymphopenia#          -  Have an active infection or positive purified protein derivative (PPD) test result#          -  Currently pregnant or lactating; or anticipate becoming pregnant.#          -  Require chronic use of steroids#          -  Have current or past HIV, hepatitis B, or hepatitis C infection#          -  Have any complicating medical issues that interfere with study conduct or  cause             increased risk#          -  Have a history of malignancies#          -  Currently using non-insulin pharmaceuticals that effect glycemic control#          -  Currently participating in another type 1 diabetes treatment study","both","8 years","45 years"
"NCT00279318","Inclusion Criteria:#          -  Newborns with high risk HLA in the general population or having a first- degree             relative affected with T1DM#          -  Newborns are less than 4 months of age#        Exclusion Criteria:#          -  Have an illness or birth defect that precludes long-term follow-up or involves use of             treatment that may alter the natural history of diabetes (e.g. steroids or insulin)#          -  Refuses to have blood and stool samples stored at the NIDDK Repository","both","","4 months"
"NCT00283218","Inclusion Criteria:#          1. Informed consent obtained before any trial-related activities.#          2. Diagnosed type 1 diabetes before the age of 40 and on insulin treatment within one             year of diagnosis.#          3. Insulin treatment of any regime for more than one year at time of inclusion.#          4. Total insulin demand >= 0,5 IU/kg/24 hrs#          5. HbA1c between 7% and 12 % (both values included).#          6. Age >= 18 years.#          7. BMI between 18 and 35 kg /m2 (including both values).#        Exclusion Criteria:#          1. Known or suspected allergy to trial product(s) or related products.#          2. Recurrent major hypoglycaemic episodes.#          3. Heart: Unstable Angina Pectoris, AMI < 12 months or heart insufficiency classified             according to NYHA III-IV#          4. Blood Pressure: Severe uncontrolled hypertension with BP > 180/110 mmHg, sitting#          5. Liver: Impaired hepatic function corresponding to serum-ALAT or –basic phosphatase >             2x upper reference limit of the local laboratory.#          6. Kidneys: Impaired renal function corresponding to serum-creatinin > 150 μmol/l             according to the local laboratory.#          7. Any disease judged by the investigator to affect the trial.#          8. Pregnancy, breast feeding or the intention of becoming pregnant or fertile women not             using adequate contraceptive measures – adequate contraceptive method is             sterilisation, hysterectomy or current use of contraceptive pills or intra uterine             device.#          9. The receipt of any investigational drug within a three month period prior to this             trial.","both","18 years",""
"NCT00284232","Inclusion Criteria:#          -  Hba1c 8% or higher, less than 1,5% variation within last year#          -  Age 18-70#          -  Multiinjections or insulin pumps#          -  Stable weight (<5kg variation last year)#          -  Mentally stable#        Exclusion Criteria:#          -  Hypoglycemia unawareness#          -  Mental incapacity","both","18 years","70 years"
"NCT00285194","Inclusion Criteria:#          1. Primary islet allotransplant#          2. Type 1 diabetes mellitus, complicated by at least one of the following situations             that persist despite intensive efforts in close cooperation with their diabetes care             team:#               1. Metabolic lability/instability;#               2. Reduced awareness of hypoglycemia;#               3. Persistently poor glucose control (as defined by HgbA1c>10% at the end of six                  months of intensive management efforts with the diabetes care team);#               4. Progressive secondary complications.#          3. Age 18 and older#          4. Able to give written informed consent#        Exclusion Criteria:#          1. Age less than 18 years#          2. Body weight greater than75 kg.#          3. BMI greater than 26 kg/m2 for male and females#          4. Waist-to-hip ratio 0.80 (female) and 0.95 (male)#          5. First degree relative with type 2 diabetes#          6. Insulin requirement of greater than 0.7 IU/kg/day#          7. HbA1C greater than 12%#          8. Positive C-peptide response to intravenous arginine stimulation#          9. Untreated proliferative retinopathy#         10. Macroalbuminuria (urinary albumin excretion greater than 300 mg/24hrs)#         11. Creatinine clearance greater than 85 ml/min/1.73 m2 in females, greater than 95             ml/min/1.73 m2 in males#         12. Serum creatinine greater than 1.2 mg/dl#         13. Previous pancreas or islet transplant#         14. Previous OKT3 antibody therapy#         15. Presence of history of panel-reactive anti-HLA antibodies greater than 10%#         16. Abnormal T4 and TSH despite thyroid replacement therapy#         17. Positive pregnancy test, or presently breast-feeding#         18. Active infection#         19. Negative screen for Epstein-Barr Virus (EBV) by an EBNA method#         20. Invasive aspergillus infection within year prior to study entry#         21. Any history of malignancy#         22. Active alcohol or substance abuse#         23. History of non-adherence to prescribed regimens#         24. Psychiatric disorder making the subject not a suitable candidate for transplantation#         25. Karnofsky performance score greater than 70#         26. Baseline Hgb greater than 11.7 g/dl; lymphopenia (greater than 1,000/L), or             leukopenia (greater than 4,000 total leukocytes/L), or an absolute CD4+ count <500/L#         27. Thrombocytopenia greater than 150 x 109/L#         28. Use of warfarin or other anticoagulant therapy (except aspirin) or patient with             PT-INR greater than 1.5#         29. Severe co-existing cardiac disease#         30. Baseline liver function tests outside of normal range#         31. Presence of gallstones on baseline ultrasound exam#         32. Active peptic ulcer disease#         33. Severe unremitting diarrhea or other gastrointestinal disorders potentially             interfering with the ability to absorb oral medications#         34. Celiac disease#         35. Hyperlipidemia (fasting LDL cholesterol greater than 130 mg/dl, treated or untreated;             and/or fasting triglycerides greater than 200 mg/dl)#         36. Addison's disease.#         37. Under treatment for a medical condition requiring chronic use of systemic steroids#         38. Any medical condition that, in the opinion of the investigator, will interfere with             the safe completion of the trial","both","18 years","65 years"
"NCT00285233","Inclusion Criteria:#          1. Primary islet allotransplant#          2. Type 1 diabetes mellitus, complicated by at least one of the following situations             that persist despite intensive efforts in close cooperation with their diabetes care             team:#               1. Metabolic lability/instability;#               2. Reduced awareness of hypoglycemia;#               3. Persistently poor glucose control (as defined by HgbA1c>10% at the end of six                  months of intensive management efforts with the diabetes care team);#               4. Progressive secondary complications.#          3. Age 18 and older#          4. Able to give written informed consent#        Exclusion Criteria:#          1. Known hypersensitivity to rabbit proteins.#          2. Presence of history of panel-reactive anti-HLA antibodies (>10%).#          3. Insufficient cardiovascular reserve.#          4. Creatinine clearance <60 mL/min/m2.#          5. Portal hypertension, abnormal liver enzyme tests, or history of significant liver             disease.#          6. History of malignancy within 5 years.#          7. Active peptic ulcer disease.#          8. Severe unremitting diarrhea or other gastrointestinal disorders potentially             interfering with the ability to absorb oral medications.#          9. Pregnancy or breast-feeding.#         10. Active infections.#         11. Serological evidence of infection with HIV, or HBsAg or HCVAb positive within the             previous 12 months prior to transplantation.#         12. Negative screen for Epstein-Barr Virus (EBV) by an EBNA method#         13. Evidence of infiltrate, cavitation, or consolidation on chest x-ray during pre-study             screening.#         14. Schizophrenia, bipolar disorder, or major depression that is unstable or uncontrolled             on current medications.#         15. Ongoing substance abuse; drug or alcohol.#         16. Recent history of noncompliance.#         17. Any medical condition that, in the opinion of the investigator, will interfere with             the safe completion of the trial.","both","18 years","65 years"
"NCT00286624","Inclusion Criteria:#          -  Primary islet allotransplant#          -  Patients with type 1 diabetes mellitus under intensive insulin management#          -  Age 18 or older#          -  Ability to give written informed consent#        Exclusion Criteria:#          -  Age less than 18 years.#          -  BMI >26 kg/m2.#          -  Insulin requirement of > 50 IU per day.#          -  Positive C-peptide response to intravenous arginine stimulation.#          -  Untreated proliferative retinopathy.#          -  Creatinine clearance < 60 ml/min/1.73 m2 for females and 70 ml/min/1.73 m2 for males.#          -  Serum creatinine >1.3 mg/dl for females, >1.5 mg/dl for males.#          -  Previous pancreas or islet transplant.#          -  Presence of history of panel-reactive anti-HLA antibodies >10%.#          -  Positive pregnancy test, or presently breast-feeding, or failure to follow effective             contraceptive measures.#          -  Active infection including hepatitis C, hepatitis B, HIV, or TB (or under treatment             for suspected TB).#          -  Negative screen for Epstein-Barr Virus (EBV).#          -  Invasive aspergillus infection within year prior to study entry.#          -  History of malignancy.#          -  Active alcohol or substance abuse#          -  History of non-adherence to prescribed regimens.#          -  Psychiatric disorder making the subject not a suitable candidate for transplantation.#          -  Inability to provide informed consent.#          -  Baseline Hgb < 11.7 g/dl in females, or < 13 g/dl in males; lymphopenia             (<1,000/microL), or leukopenia (<3,000 total leukocytes/microL), or an absolute CD4+             count <500/microL., or platelets <150,000/microL#          -  History of coagulopathy or medical condition requiring long-term anticoagulant             therapy after transplantation or patient with INR >1.5.#          -  Severe co-existing cardiac disease.#          -  Baseline liver function tests outside of normal range or history of significant liver             disease.#          -  Active peptic ulcer disease.#          -  Severe unremitting diarrhea or other gastrointestinal disorders potentially             interfering with the ability to absorb oral medications.#          -  Presence of severe allergy requiring acute or chronic treatment, or hypersensitivity             to drugs similar to RAD (e.g., macrolides).#          -  Known hypersensitivity to rabbit proteins.#          -  Hyperlipidemia (fasting LDL cholesterol > 130 mg/dl, treated or untreated; and/or             fasting triglycerides > 200 mg/dl).#          -  Addison's disease.#          -  Under treatment requiring chronic use of systemic steroids.#          -  Any medical condition that, in the opinion of the investigator, will interfere with             the safe completion of the trial.","both","18 years","65 years"
"NCT00286962","Inclusion Criteria:#          -  Type 1 diabetes mellitus#          -  Intermediate or poor glycemic control, defined as HbA1c >= 7,5% AND/OR >= 5 incidents             of hypoglycemia a week.#        Exclusion Criteria:#          -  renal function impairment: creatinin >= 150 micromol/L or a creatinin clearance < 50             ml/min#          -  Cardiac problems: decompensated heart failure (NYHA III and IV); diagnosis of             unstable angina pectoris; myocardial infarction within the last 12 months#          -  Known or suspected allergy against insulin or any component of the composition#          -  Mental retardation or psychiatric treatment for schizophrenia, organic mental             disorder or bipolar disorder currently or in the past.#          -  Severe untreated proliferative retinopathy.#          -  Insufficient knowledge of the Dutch language to understand the requirements of the             study.#          -  Current use of systemic corticosteroids or suffering from a condition which caused             systemic corticosteroid use more than once in the last year.#          -  Substance abuse, other than nicotine#          -  A history of cancer, excluding well differentiated thyroid carcinoma, breast             carcinoma without lymph node metastases and skin carcinoma#          -  Participation in other trials, involving investigational products within 30 days             prior to trial entry.#          -  Plans to engage in activities which require them to go below 25 feet below sea level.#          -  Any condition that the Investigator and/or Coordinating Investigator feels would             interfere with trial participation or evaluation of results.","both","18 years","70 years"
"NCT00290043","Inclusion Criteria:#          -  Type 1 diabetes mellitus#        Exclusion Criteria:","both","18 years","75 years"
"NCT00290979","Inclusion Criteria:#          -  Men or women with type 1 diabetes mellitus, an HbA1C range of >=6.0 - =<11.0%, and on             a basal-bolus insulin regimen. They must have had at least 1 year of continuous             insulin treatment at the date of informed consent.#        Exclusion Criteria:#          -  Subjects who received an oral hypoglycemic agent other than insulin within 4 weeks             prior to informed consent#          -  Subjects who received oral or intravenous corticosteroid within 4 weeks prior to             informed consent#          -  Subjects who were treated with another investigational product within 12 weeks prior             to informed consent#          -  Subjects with likelihood of requiring concomitant treatment during the study period             with drugs not permitted by this study protocol#          -  Subjects with clinically relevant cardiovascular, hepatic, neurologic, endocrine,             active cancer, other serious complication or systemic disease making implementation             of the protocol or interpretation of the study results difficult#          -  Subjects who have undergone pancreatectomy or pancreas/islet cell transplant#          -  Night shift workers#          -  Subjects unlikely to comply with the study protocol, e.g., inability to periodic             return for follow-up visits, and unlikelihood of completing the study#          -  Subjects who have previously been treated with HMR1964#          -  Subjects who are pregnant, breast feeding or wish to become pregnant during the study             period#          -  Female subjects who are possibly pregnant [female subjects of reproductive potential             who have serum human chorionic gonadotropin (hCG) level > 0.7 mIU/mL as determined by             central laboratory, SRL Medisearch Inc., during screening phase]#          -  Subjects with diabetic retinopathy who received surgical treatments (laser             photocoagulation or vitrectomy) within 24 weeks prior to informed consent, or who are             expected to have these surgical treatments during the study period#          -  Subjects with history of alcohol abuse#          -  Subjects with hypersensitivity to insulin preparations#          -  Subjects with impaired hepatic function (SGOT or SGPT ³=<80 IU/L determined by             central laboratory, SRL Medisearch Inc., during screening phase) or impaired renal             function (serum creatinine =<2.0 mg/dL determined by central laboratory, SRL             Medisearch Inc., during screening phase)#          -  Subjects who are judged by the investigator or subinvestigator as inappropriate as             the subjects of this study for any other reason","both","18 years",""
"NCT00291772","Inclusion Criteria:#        These children will be subjects of the Texas Children's Hospital Diabetes Care Center. The        subjects must be#          1. 13-22 years of age at the time of enrollment.#          2. Have been diagnosed with diabetes for at least 1 year and in good control (HbA1C less             than or equal to 8.5%).#          3. Be on continuous subcutaneous insulin infusion using an insulin pump.#          4. Subjects must be otherwise healthy except for their T1DM and treated hypothyroidism.#          5. Menstruating women must have a negative pregnancy test.#          6. Hemoglobin equal to or greater than 12 g/dL before each study.#          7. Weight more than 44 kg. -#        Exclusion Criteria:#          1. Age greater than 23 years or less than 13 years at the time of study#          2. Any chronic disease: leukemia, asthma, inflammatory bowel disease, cystic fibrosis,             juvenile rheumatoid arthritis, etc or on treatment that might directly or indirectly             affect glucose homeostasis, except for diabetes and hypothyroidism stable on             medications#          3. Anemia (hemoglobin less than 12mg/dl)#          4. Lack of a supportive family environment#          5. Positive pregnancy test in menstruating young women#          6. Evidence or history of chemical abuse#          7. Hgb A1C greater than 8.5 % in a diabetic subject#          8. BMI > 90 % tile for age or < 10 % tile for age#          9. Weight less than 44 kg.  -","both","13 years","22 years"
"NCT00297401","Inclusion Criteria:#          -  have type 1 diabetes mellitus#          -  hemoglobin A1C between 6 and 10%#          -  have evidence of early diabetic renal disease as determined by creatinine clearance             more than 80 ml/minute, urine albumin to creatinine ratio of more than 3.0 and             urinary albumin levels consistent with the diagnosis of diabetic nephropathy (more             than 20 mg/mmol for men and more than 28 mg/mmol for women)#          -  are without language barrier, cooperative, expected to return for all follow-up             visits, and who give informed consent before entering the study's randomization phase             and after being informed of the study medications and procedures.#        Exclusion Criteria:#          -  Have poorly controlled diabetes, chronic liver disease, clinical jaundice, and/or             elevation of liver-related laboratory results, have chronic renal failure on             dialysis, have received a kidney transplant or have a moderate to severe kidney             disease, have previous history of myocardial infarction, stroke, claudication or             amputation, have cancer and are currently receiving chemotherapy or plan to receive             chemotherapy in the next 6 months and woman of childbearing potential despite             actively practicing birth control by using a medically accepted device or therapy.#          -  are being treated or intending to start treatment during the trial with excluded             drugs: topical or oral carbonic anhydrase inhibitors and require more than 2 weeks of             treatment with drugs known to strongly inhibit cytochrome P450 3A4 (CYP3A4),             including but not limited to, delavirdine, fluconazole, itraconazole, indinavir,             ketoconazole mibefradil, nelfinavir, ritonavir, and saquinavir.#          -  consume alcohol, tobacco and nicotine products within 48 hours before the study  and             have any condition that, in the investigator's opinion, would preclude meaningful             participation in the study, including, but not limited to, abnormal laboratory values             the investigator considers clinically significant, patients who are poor medical or             psychiatric risks for treatment with an investigational drug, patients who are             unlikely to complete the study.#          -  suspected or proven to have a kidney disease other than diabetic related albuminuria             and/or renal insufficiency.","both","18 years",""
"NCT00297583","Inclusion criteria#          -  Type 1 diabetes (as defined by the World Health Organization) for at least 2 years#          -  HbA1c <= 10.0 %#          -  C-peptide < 0.05 nmol/L, based on fasting C-peptide level#          -  Body mass index (BMI) <= 30 kg/m²#          -  Treatment with intensified insulin therapy: short acting insulin before meals             (breakfast, lunch,dinner) with neutral protamine Hagedorn (NPH) insulin, or             continuous subcutaneous insulin infusion (CSII) for at least 3 months.Insulin             glargine, or other basal insulin than NPH, had to be replaced by NPH insulin at the             screening visit.#          -  Women not of childbearing potential (surgically sterile, or postmenopausal for more             than 2 years) or not pregnant and agreed to use a reliable contraceptive measure for             the duration of the study.#          -  Able and willing to perform self-monitoring of blood glucose#        Exclusion criteria#          -  Contraindications from:#               -  The medical history and physical examination#               -  Laboratory tests (hematology, clinical chemistry and urinalysis)#               -  12-lead electrocardiogram (ECG)#               -  Blood pressure and pulse rate#               -  Hepatitis screen#          -  Pregnancy, breast-feeding or intention to become pregnant#          -  History of drug or alcohol abuse#          -  Receipt of any investigational drug within the last 30 days prior to this trial#          -  Experienced recurrent severe hypoglycemia or hypoglycemic unawareness (as judged by             the investigator)#          -  Total daily insulin dose >= 1.4 IU/kg#          -  Serum insulin antibody level > 20 U/mL determined at screening visit#          -  Smokers > 10 cigarettes per day or equivalent#          -  Pre-planned surgery during the study#          -  Currently being treated with systemic corticosteroids or any other drugs affecting             blood glucose, or immunosuppressives#          -  Known diabetic gastroparesis or lipodystrophia#          -  Active proliferative diabetic retinopathy, as defined by the application of focal or             panretinal photocoagulation or vitrectomy, in the 6 months prior to visit 1, or any             other unstable (rapidly progressing) retinopathy that may require surgical treatment             (including laser photocoagulation) during the study#          -  Cardiac problems:#               -  New York Heart Association (NYHA) Functional Capacity Class III and IV#               -  Diagnosis of unstable angina pectoris#               -  Myocardial infarction within the last 12 months#          -  Biochemical signs of hepatic or renal diseases as indicated by alanine             aminotransferase and/or alkaline phosphatase >= 2 times and/or creatinine >= 1.5 times             the upper limit of the normal reference range for the age group or current renal             dialysis#          -  Anemia as indicated by hemoglobin < 6.2 mmol/L or clinically relevant iron deficiency             as indicated by low ferritin levels in men (< 34 ng/mL) and women (premenopausal < 22             ng/mL, menopausal < 13 ng/mL)#          -  Any other clinically significant major organ system disease such as relevant             cardiovascular (e.g. uncontrolled hypertension), gastrointestinal, hepatic,             neurologic, endocrine (e.g.pancreatic), hematologic, malignant or other major             systemic diseases making implementation of the protocol or interpretation of the             study results difficult#          -  Significant endogenous insulin secretion indicated by fasting C-peptide#          -  History of hypersensitivity to insulin or insulin analogues or any of the excipients             in the HMR#          -  Donation of blood (>500 mL) during the previous 3 months prior to the screening visit             or during the duration of the study","both","18 years","70 years"
"NCT00297635","Inclusion Criteria:#        Patients must reside in the Philadelphia area and participate in regular in person visits        to the Jefferson Diabetes Research Center. Patients must be at the stage of their        treatment where they are going to initiate insulin infusion pump therapy. Patients must be        at least 18 years of age before starting the protocol and must have never used an insulin        pump before.  Ideally, at least a few of the study participants will use English as a        second language.  Since the technology is capable of delivering messages to the wireless        email device in several languages including Spanish and French, there is no English only        requirement.  Likewise, patients not capable of operating the wireless email device will        be included since the GlucoMON device is specially designed to enable patient use without        technology aptitude typical for personal computers and interactive wireless devices.#        Exclusion Criteria:#        Patients living outside the Philadelphia area and those that are not immediately going to        initiate insulin pump therapy wil be excluded. Patients unwilling to perform at least 4        blood glucose self-tests will be ineligible for participation in this study.  Conventional        guidelines for minimum self-care will apply including criteria for discontinuance of        insulin pump therapy.","both","18 years",""
"NCT00298740","Inclusion Criteria:#          -  People with type 1 diabetes previously implanted with the MiniMed Implantable Pump             model 2000 at Johns Hopkins may join this study.#        Exclusion Criteria:#          -  Anyone not previously implanted with the MiniMed Implantable Pump model 2000 at Johns             Hopkins.","both","",""
"NCT00303134","Inclusion Criteria:#        - Enrolling subjects must have Type 1 diabetes mellitus for more than 5 years, complicated        by at least one of the following situations that persist despite intensive insulin        management efforts.  (Intensive management is defined as monitoring of glucose values at        home no less than three times each day and by the administration of three or more insulin        injections each day.  Such management must be monitored in close cooperation with an        endocrinologist or primary care physician, as defined by at least three contacts during        the previous 12 months. If an endocrinologist did not participate in the ongoing        management effort during the past year, then an independent endocrinologist must assess        the adequacy of the management efforts prior to enrollment.)  The complicating situations        are:#        a. Reduced awareness of hypoglycemia, as defined by the absence of adequate autonomic        symptoms at plasma glucose levels of < 54 mg/dL, b. Metabolic lability/instability,        characterized by two or more episodes of severe hypoglycemia and which is associated with        a blood glucose below 54 mg/dl OR two or more hospital visits for diabetic ketoacidosis        over the last year, c. Despite efforts at optimal glucose control, progressive secondary        complications of diabetes as defined by: i) Retinopathy—a minimum of a three step        progression using the Early Treatment Diabetic Retinopathy Study (ETDRS) grading system        44,or an equivalent progression as certified by an ophthalmologist familiar with diabetic        retinopathy, or ii) Nephropathy—a confirmed rise of 50 µg/min (72 mg/24h) of        microalbuminuria or greater over at least three months (beginning anytime within the past        two years) despite the use of an ACE inhibitor, or iii) Neuropathy—persistent or        progressing autonomic neuropathy (gastroparesis, postural hypotension, neuropathic bowel        or bladder) or persistent or progressing severe peripheral painful neuropathy not        responding to usual management (e.g., tricyclics, gabapentin, or carbamazepine).#        Exclusion Criteria:#          1. Severe co-existing cardiac disease, characterized by any one of these conditions:#               -  Recent myocardial infarction (within past six months), or#               -  Angiographic evidence of non-correctable coronary artery disease, or#               -  Evidence of ischemia on functional cardiac exam (functional testing is required                  for all subjects, with a stress echo test recommended for subjects with a                  history of ischemic disease).  Patients unable to perform an exercise stress                  echocardiogram test will undergo adenosine vasodilator stress test, and if there                  is a history of bronchospasm, will undergo dobutamine stress test.#          2. Active alcohol or substance abuse-includes cigarette smoking (must be abstinent for             six months).  Active alcohol abuse should be considered using the current NIAAA             definitions, whereby alcohol abuse is defined by a pattern of drinking that is             accompanied by one or more of the following situations within a 12-month period:#               -  Failure to fulfill major work, school, or home responsibilities;#               -  Drinking in situations that are physically dangerous, such as while driving a                  car or operating machinery;#               -  Recurring alcohol-related legal problems, such as being arrested for driving                  under the influence of alcohol or for physically hurting someone while drunk;#               -  Continued drinking despite having ongoing relationship problems that are caused                  or worsened by the effects of alcohol.#          3. Psychiatric disorder making the subject not a suitable candidate for transplantation,             e.g., schizophrenia, bipolar disorder, or major depression that is unstable or             uncontrolled on current medication.  (A psychological or psychiatric consultation is             required only if considered necessary by some current indication or history.)#          4. History of non-adherence to prescribed regimens#          5. Active infection including hepatitis C, hepatitis B, HIV, or TB (or under treatment             for suspected TB)#          6. Any history of or current malignancies except squamous or basal skin cancer#          7. BMI > 26 kg/m2#          8. C-peptide response to arginine stimulation (5 gm I.V.) (any C-peptide >= 0.3 ng/mL at             2, 3, 4, 5, 7 and 10 min post-infusion)#          9. Inability to provide informed consent#         10. Age less than 18 or greater than 65 years#         11. Creatinine clearance <80 mL/min/1.73 m2#         12. Serum creatinine >1.6 mg/dL#         13. Macroalbuminuria (urinary albumin excretion rate >300 mg/24h)#         14. Baseline Hb <10.5 gm/dL in women, or <13 gm/dL in men#         15. Baseline LFT's outside of normal range with the exception of Gilberts Syndrome. (An             initial LFT test panel with any values >1.5 times upper limits of normal will exclude             a patient; a re-test for any values between normal and 1.5 times normal should be             made, and if the values remain elevated above normal limits, the patient will be             excluded.)#         16. Presence of gallstones (subjects may be eligible two weeks after a laparoscopic             cholecystectomy)#         17. Portal hypertension, detected by baseline duplex ultrasonography (assessment of             direction of flow in right, left and main portal vein [antegrade (normal) or             retrograde (abnormal indicative of portal hypertension)]; hemangioma in liver on             baseline ultrasonography#         18. Untreated proliferative retinopathy#         19. Positive pregnancy test, intent for future pregnancy or male subjects' intent to             procreate, failure to follow effective contraceptive measures, or presently             breast-feeding#         20. Evidence of sensitization on PRA (determined by demonstration of positive results for             anti-HLA antibodies using solid phase immunoassay with soluble HLA Class I molecules             as a target, or a general PRA panel with reactivity >20%)#         21. Insulin requirement >0.7 IU/kg/day#         22. HbA1C >12%#         23. Inability to reach the study hospital for transplantation within 24 hrs of             notification#         24. Untreated hyperlipidemia (fasting LDL cholesterol >130 mg/dL and/or fasting             triglycerides >200 mg/dL)#         25. Treated hyperlipidemia that is uncontrolled (fasting LDL cholesterol >130 mg/dL;             and/or fasting triglycerides >200 mg/dL)#         26. Under treatment for a medical condition requiring chronic use of steroids aa.  Use of             coumadin or other anticoagulant therapy (except aspirin) or subject with PT/INR >1.5#             27.  Addison's disease.  All subjects should be screened with a basal 8:00 a.m.             cortisol test.  Results less than the lower limit of normal indicate further testing             (e.g., a Cortrosyn stimulation test) to rule out adrenal insufficiency.  Abnormal             ACTH stimulation test will be an exclusion criterion.","both","18 years","65 years"
"NCT00304538","Inclusion Criteria:#          1. Males or females, 18 to 55 years of age, requiring daily insulin for the management             of type 1 diabetes mellitus for >10 years#          2. On a stable basal insulin regimen using CSII therapy (“stable” defined as total daily             dose of insulin not changed by more than ± 20% for 2 months prior to screening)#          3. Glycosylated hemoglobin (HbA1c) <=8.0%#          4. Total daily insulin requirement of <=1 unit/kg of body weight#          5. Fasting C-peptide level of <1.0 ng/mL (<330 pmol/L) (may be done at screening or may             be taken from subject’s medical record if performed within the past 12 months)#          6. Body mass index (BMI) <=25.5 kg/m2 and body weight over past 6 months within ± 5%#          7. Hemoglobin, hematocrit, and platelets within normal limits; no clinically significant             abnormality of white blood cells (WBC) or differential#          8. Serum chemistry results within normal limits except for liver enzymes [aspartate             transaminase (AST) and alanine transaminase (ALT)] which must be within 2.5 times             upper limit of normal (ULN) and creatinine which must be <1.6 mg/dL#          9. Normal thyroid stimulating hormone#         10. No history of HIV infection and negative results for hepatitis B and C#         11. Negative serum pregnancy test, non-lactating, and using adequate contraception, if             female and of child bearing potential (intact uterus and pre-menopausal)#         12. Medications for the treatment of high blood pressure and/or dyslipidemia are allowed             if regimen stable for 2 months prior to screening#         13. Medically stable as determined by history and physical examination, including vital             signs#         14. Electrocardiogram (ECG) shows no acute ischemia or clinically significant abnormality#         15. Willing and able to give written informed consent#        Exclusion Criteria:#          1. Participation in a clinical trial with or use of an investigational agent within 30             days of Study Visit 1.#          2. History of atherosclerosis including coronary artery disease, angina pectoris,             myocardial infarction, cerebrovascular accident, or transient ischemic attacks#          3. History or symptoms of pheochromocytoma#          4. History of any malignancy within 3 years except for basal cell skin cancer#          5. Active infection, drug or alcohol abuse, eating disorder, or psychiatric disorder#          6. Concomitant medications:  systemic or potent topical steroids or medications that may             affect blood glucose, e.g., sulfonylureas, alpha-glucosidase inhibitors, biguanides,             meglitinides, thiazolidinediones#          7. Any condition which increases the risk of participation in the trial in the opinion             of the investigator -","both","18 years","55 years"
"NCT00305344","Inclusion Criteria:#          1. Must have a diagnosis of T1D and have stored umbilical cord blood in an AABB and/or             FACT accredited cord bank.#          2. TID diagnosis will be defined as having a clear history of polydipsia, polyphagia,             polyuria, and weight loss consistent with a clinical diagnosis, diagnosis will mot be             based solely upon the presence of autoantibodies.#          3. Cord blood meets all selection and testing criteria (see below).#          4. Able to complete mixed meal tolerance / glucagon stimulation test.#          5. Normal screening values for CBC, Renal function and electrolytes (BMP).#          6. Willing to comply with intensive diabetes management#        Exclusion Criteria:#          1. Complicating medical issues that would interfere with blood drawing or monitoring.#          2. Chronic use of steroids or other immunosuppressive agents for other conditions.#          3. Positive infectious disease markers from mothers' blood or cord at time of collection             (See below for details).#          4. Any evidence of illness on planned infusion date (i.e. fever >38.5 C, vomiting,             diarrhea, wheezing, or crackles).","both","1 year",""
"NCT00306098","Inclusion Criteria:#          1. Patients between 18 and 65 years of age#          2. Patients with type 1 diabetes mellitus for more than 5 years duration#          3. One or more of the following:#               -  Hypoglycemia unawareness - judged by history of blood sugars <54 on glucometer                  without symptoms and/or hypoglycemic episodes requiring assistance from  either                  family, glucagon administration or emergency services#               -  Poor diabetes control (HbA1c>8% or >2 visits/yr to hospital for treatment of                  ketoacidosis) despite intensive insulin therapy#               -  Progressive complications of type 1 diabetes mellitus#          4. Body Mass Index (BMI) <=26#        Exclusion Criteria:#          1. c-peptide > 0.3ng/ml basal or stimulated;#          2. untreated proliferative diabetic retinopathy;#          3. HbA1C >12%;#          4. creatinine clearance <60;#          5. serum creatinine consistently >1.6 mg/dl;#          6. macroalbuminuria >300mg albumin in 24 hours;#          7. presence of panel reactive antibodies (PRA) >20%;#          8. previous/concurrent organ transplantation (except previous unsuccessful islet cell             transplant;#          9. malignancy or previous malignancy (except non-melanomatous skin cancer);#         10. x-ray evidence of pulmonary infection;#         11. active infections;#         12. active peptic ulcer disease, gall stones, hemangioma, or portal hypertension#         13. serological evidence of HIV, HbsAg or HCV; serological evidence of active EBV             (IgM>IgG) or EBV negative serology;#         14. PPD conversion or positive PPD without historic completion of appropriate             prophylactic treatment;#         15. abnormal liver function test;#         16. anemia (hemoglobin <12.0);#         17. hyperlipidemia (fasting serum triglycerides >200mg/dl and/or fasting serum             cholesterol >240 mg/dl and/or fasting LDL cholesterol >140 mg/dl);#         18. BMI above 26;#         19. unstable cardiovascular status; prostate specific antigen (PSA) >4;#         20. pregnancy or breastfeeding;#         21. sexually-active females who are not: a) post-menopausal, b) surgically sterile, or c)             not using an acceptable method of contraception (oral contraceptives, Norplant,             Depo-Provera, and barrier devices are acceptable; condoms used alone are not             acceptable);#         22. alcohol abuse, substance abuse or smoking within the previous 6 months; insulin             requirement >1u/kg/day and any condition or any circumstance that makes it unsafe to             undergo an islet cell transplant.","both","18 years","65 years"